All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Neuropeptides and neuromodulators are secreted via Ca^2+^-dependent fusion of dense-core vesicles (DCVs) found in axons and dendrites of most neurons in the brain. Upon binding to their receptors, the secreted molecules modulate synaptic function \[[@pbio.3000826.ref001], [@pbio.3000826.ref002]\] and synaptic plasticity. One of the well-documented examples is how brain-derived neurotrophic factor (BDNF) facilitates long-term potentiation (LTP) and learning \[[@pbio.3000826.ref003], [@pbio.3000826.ref004]\]. However, the mechanism by which molecules like BDNF are secreted from DCVs is still a poorly defined element. DCV exocytosis is strictly Ca^2+^-dependent and requires higher frequency stimulation than synaptic vesicle exocytosis \[[@pbio.3000826.ref005], [@pbio.3000826.ref006]\]. Several studies in invertebrates \[[@pbio.3000826.ref007]--[@pbio.3000826.ref009]\] and one in mouse cortical neurons \[[@pbio.3000826.ref010]\] have proposed that Ca^2+^/calmodulin-dependent protein kinase 2 (CaMKII) is involved in DCV exocytosis. This would be consistent with the fact that both secretion of neuromodulators and activation of the kinase \[[@pbio.3000826.ref011], [@pbio.3000826.ref012]\] requires high-frequency stimulation. Hence, CaMKII may, in concert with its firmly established role in LTP-induction, upstream of alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor insertion and--phosphorylation \[[@pbio.3000826.ref013]--[@pbio.3000826.ref015]\], also be responsible for neuromodulator secretion from DCVs to contribute to plasticity phenomena like LTP.

Of the 4 genes that encode CaMKII proteins, α and βCaMKII are the most abundant isoforms expressed in neurons \[[@pbio.3000826.ref016]--[@pbio.3000826.ref018]\] and share more than 90% homology in their catalytic domain \[[@pbio.3000826.ref017]\]. Generally, βCaMKII has a nonenzymatic function binding to filamentous actin (F-actin) and positioning the holoenzyme, together with αCaMKII, at the postsynaptic density (PSD) after Ca^2+^ influx through N-methyl-D-aspartate (NMDA) receptors \[[@pbio.3000826.ref019]--[@pbio.3000826.ref021]\]. Once activated, αCaMKII initiates a phosphorylation cascade with targets from AMPA receptors \[[@pbio.3000826.ref012], [@pbio.3000826.ref022]\], to motor proteins \[[@pbio.3000826.ref023]\] and cytoskeleton components \[[@pbio.3000826.ref024]\]. In addition, γCaMKII shuttles CaM to the nucleus promoting CaMKIV activation and therefore indirectly regulates transcription via phosphorylation of cAMP-response element binding protein (CREB) \[[@pbio.3000826.ref025]--[@pbio.3000826.ref027]\], which promotes the transcription of BDNF \[[@pbio.3000826.ref028]--[@pbio.3000826.ref030]\]. At the presynaptic side, CaMKII regulates presynaptic plasticity \[[@pbio.3000826.ref031]\] by limiting the ready releasable pool of synaptic vesicles (SVs) \[[@pbio.3000826.ref032]\]. In *Drosophila* neuromuscular junction (NMJ), pharmacological inhibition of CaMKII reduces both the mobility of DCVs inside synaptic boutons \[[@pbio.3000826.ref007], [@pbio.3000826.ref033]\] and the synaptic capture of DCVs traveling through the axon \[[@pbio.3000826.ref008], [@pbio.3000826.ref034]\], causing failures in neuropeptide secretion after high-frequency stimulation \[[@pbio.3000826.ref007]\]. In mice, similar pharmacological inhibition delays BDNF exocytosis in dendrites \[[@pbio.3000826.ref010]\]. In *Caenorhabditis elegans*, loss of the CaMKII homolog UNC-43 leads to a drastic reduction of neuropeptides at synapses, but their accumulation in coelomocytes was unaltered \[[@pbio.3000826.ref009]\], i.e., suggesting that secretion, per se, opposite to what was reported in *Drosophila*, was not affected. Hence, despite some contrasting findings, these studies suggest that CaMKII is involved in efficient positioning and possibly also the release of neuropeptides and neuromodulators from DCVs.

In this study, α- and βCaMKII double-knockout (DKO) hippocampal neurons were used to investigate the role of CaMKII in neuropeptide and neuromodulator trafficking and exocytosis. Using a combination of cellular and single-vesicle approaches, we confirmed that CaMKII indeed regulates the amount of secreted neuromodulators. However, we found that the efficiency of individual DCV fusion events was unaffected and that the fraction of fusing vesicles remained the same in the absence of α- and βCaMKII. Instead, we discovered that the reduced secretion of neuromodulators was entirely due to a decreased neuropeptide/neuromodulator content in synapses and a decreased number of DCVs entering the axons of DKO neurons. The decreased neuropeptide content was explained by a robust and selective reduction in the expression of DCV cargo in DKO neurons. Blocking BDNF secretion or antibody scavenging of secreted BDNF in wild-type (WT) neurons produced a similar reduction. Reduced neuromodulator expression in αβCaMKII DKO neurons was restored by active βCaMKII, but not inactive βCaMKII or αCaMKII, and by 3 CaMKII downstream effectors that promote CREB phosphorylation (pCREB). We conclude that in mammalian CNS neurons, CaMKII regulates neuromodulation as a crucial component of a feedback loop that up-regulates expression of DCV-resident neuromodulators dependent on their secretion. In addition, CaMKII regulates axonal targeting of neuromodulators but not DCV transport or fusion.

Results {#sec002}
=======

CaMKII facilitates neuropeptide secretion {#sec003}
-----------------------------------------

To understand the role of CaMKII in neuropeptide secretion, we used αCaMKII and βCaMKII conditional DKO mice \[[@pbio.3000826.ref035]\]. Hippocampal neuron cultures were infected with Cre-recombinase (DKO) or an inactive form of Cre \[[@pbio.3000826.ref036]\] (WT) on the day of plating (day in vitro, DIV0) ([Fig 1A](#pbio.3000826.g001){ref-type="fig"}), producing complete knockout of both α and βCaMKII at DIV17 ([Fig 1B](#pbio.3000826.g001){ref-type="fig"}). To investigate DCV fusion, we performed live-cell imaging of the DCV cargo BDNF-pHluorin \[[@pbio.3000826.ref037]\] ([Fig 1C](#pbio.3000826.g001){ref-type="fig"}), which allowed us to probe neuropeptide exocytosis at single-vesicle resolution ([Fig 1D](#pbio.3000826.g001){ref-type="fig"} and [S1 Movie](#pbio.3000826.s001){ref-type="supplementary-material"}). Neurons were stimulated twice with 8 bursts of 1 second at 50 Hz to trigger DCV fusion \[[@pbio.3000826.ref006]\], and individual BDNF-pHluorin fusion events ([Fig 1E](#pbio.3000826.g001){ref-type="fig"}) were counted. The number of BDNF-pHluorin fusion events was lower in DKO neurons compared with WT (WT = 515 ± 281.11; DKO = 282 ± 153.15 *p* = 0.0575; [Fig 1G](#pbio.3000826.g001){ref-type="fig"}). This reduction indicates that neuromodulators, such as BDNF, require CaMKII for efficient secretion, as suggested in *Drosophila* NMJ \[[@pbio.3000826.ref007]\] and by pharmacological inhibition in mouse \[[@pbio.3000826.ref010]\].

![CaMKII regulates neuromodulation.\
(A) Schematic representation of the experimental design. Neuronal cultures from floxed αβCaMKII P1 pups were infected at DIV0 with Cre-recombinase to generate DKO neurons and with inactive Cre as control. Cultures were infected at DIV11 with BDNF-pHluorin as exocytosis reporter, and live-cell imaging was performed at DIV17. (B) Typical Western blot showing the complete KO for both α and βCaMKII. (C) Schematic representation of DCV fusion assay. DCVs are labeled with BDNF-pHluorin, and neurons are stimulated with 2 trains of 8 bursts of 50 APs at 50 Hz (light blue bars). (D) Representative neurons expressing CFP driven by CaMKII promoter superimposed with BDNF-pHluorin events (green dots). Insert shows a neurite at resting state (left) and upon stimulation (marked by light blue bars on the right). (E) Kymographs of BDNF-pHluorin fusion events. Individual DCV fusion events, black dots in the images, were quantified semi-automatically. (F) Histogram of the average number of DCV fusion events per cell during stimulation (light blue bars). (G) Total number of BDNF-pHluorin release events per cell. (H) Typical example of BDNF-pHluorin fusion events at synapses visualized by Synapsin-mCherry (dashed lines) and at extrasynaptic sites. (I) Percentage of BDNF-pHluorin fusion events at synapses. Traces show mean ± SEM (shaded area); boxplots with 95% CI whiskers, the white cross represents mean ± SEM, and the central bar is median. Columns and dots represent individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}; original Western blot can be found in S1 Raw images. \**p* = 0.057. Scale bar = 25 μm (D); 5 μm (D insert); 10 μm (I). AP, action potential; BDNF, brain-derived neurotrophic factor; CaMKII, Ca2+/calmodulin-dependent kinase II; CFP, cyan fluorescence protein; CI, confidence interval; DCV, dense-core vesicle; DIV, day in vitro; DKO, double-knockout; WT, wild type.](pbio.3000826.g001){#pbio.3000826.g001}

The majority of DCVs fuse at synapses \[[@pbio.3000826.ref038], [@pbio.3000826.ref039]\]. In *Drosophila*, CaMKII inhibition reduces the amount of DCV fusion at the NMJ synapse \[[@pbio.3000826.ref007]\]. We investigated the localization of BDNF-pHluorin fusion events ([Fig 1H](#pbio.3000826.g001){ref-type="fig"}) and observed no differences in the percentage of BDNF-pHluorin fusion events that occurred at Synapsin-mCherry marked synapses (WT = 68.18% ± 4.42; DKO = 71.81% ± 3.54 *p* = 0.106; [Fig 1I](#pbio.3000826.g001){ref-type="fig"}). Thus, CaMKII facilitates the secretion of neuromodulators both at synaptic as well as at extrasynaptic locations.

To assess the specificity for neuropeptide transmission, we used Synaptophysin-pHluorin (SypHy) \[[@pbio.3000826.ref040]\] to analyze SV transmission ([S1 Fig](#pbio.3000826.s004){ref-type="supplementary-material"}). SypHy fluorescence was quantified during electrical field stimulation of 5 s at 40 Hz, which activated the majority of synapses (WT = 95.05 ± 4.60; DKO = 93.04 ± 3.56 *p* = 0.4431; [S1 Fig](#pbio.3000826.s004){ref-type="supplementary-material"}), containing equal levels of SypHy-positive vesicles ([S1 Fig](#pbio.3000826.s004){ref-type="supplementary-material"}). As suggested in previous studies in αCaMKII KO \[[@pbio.3000826.ref032]\] as well as α- and βCaMKII DKO \[[@pbio.3000826.ref022], [@pbio.3000826.ref035]\], increase in SypHy signal during stimulation ([S1 Fig](#pbio.3000826.s004){ref-type="supplementary-material"}), as well as its decay during the recovery period ([S1 Fig](#pbio.3000826.s004){ref-type="supplementary-material"}), was comparable between DKO and WT neurons. We, therefore, concluded that CaMKII contributes to neuropeptide exocytosis specifically over synaptic transmission.

CaMKII affects the number of DCVs, not their fusion {#sec004}
---------------------------------------------------

To investigate the mechanism of reduced BDNF secretion, we measured the fraction of DCVs that fused upon stimulation \[[@pbio.3000826.ref006]\]. Strikingly, the total number of pHluorin-labeled DCVs, quantified upon brief NH~4~Cl superfusion ([Fig 2A](#pbio.3000826.g002){ref-type="fig"}), was reduced by 43% in DKO neurons compared with WT (WT = 7.72 × 10^3^ ± 1.19 × 10^3^; DKO = 4.44 × 10^3^ ± 386; *p* = 0.0124; [Fig 2B](#pbio.3000826.g002){ref-type="fig"}). The same effect is also observed as a leftward shift in the histogram of total DCVs/per cell ([S1 Fig](#pbio.3000826.s004){ref-type="supplementary-material"}). The reduction in pHluorin-labeled DCVs was not due to a defect in acidification of the vesicles, because the baseline fluorescence was comparable in the 2 genotypes (WT = 1 ± 0.017; DKO = 0.961 ± 0.019; *p* = 0.1437 [S2 Fig](#pbio.3000826.s005){ref-type="supplementary-material"}). Taking into account the lower number of pHluorin-labeled DCVs, the fraction of DCVs fusing in DKO neurons that was similar to WT (WT = 6.83% ± 2.4; DKO = 5.6% ± 2.2; *p* = 0.3575; [Fig 2C and 2D](#pbio.3000826.g002){ref-type="fig"}), indicating that CaMKII does not control the DCV fusion process itself but regulates the number of available DCVs.

![CaMKII regulates DCV content but not their fusion efficiency.\
(A) Schematic representation of DCV fusion assay. DCVs are labeled with BDNF-pHluorin, and neurons are stimulated with 2 trains of 8 bursts of 50 APs at 50 Hz (light blue bars). At the end of the stimulation, the bath application of NH~4~Cl dequenches all BDNF-pHluorin-containing vesicles. Right, representative neurons with BDNF-pHluorin-labeled vesicles dequenched. (B) Total number of DCVs per cell quantified upon NH~4~^+^ superfusion. (C) Cumulative fraction of DCV fusion events during stimulation. The fraction is calculated as the number of DCVs fusing per frame divided by the total number of BDNF-pHluorin puncta per neuron. (D) Fraction of BDNF-pHluorin-labeled DCV fusing during stimulation. Traces show mean ± SEM (shaded area); boxplots with 95% CI whiskers, the white cross represents mean ± SEM, and the central bar is median. Columns and dots represent individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p* \< 0.05. Scale bar = 25 μm (A). AP, action potential; BDNF, brain-derived neurotrophic factor; CaMKII, Ca2+/calmodulin-dependent kinase II; CI, confidence interval; DCV, dense-core vesicle; DIV, day in vitro; DKO, double-knockout; WT, wild type.](pbio.3000826.g002){#pbio.3000826.g002}

The reduced signal upon NH~4~Cl superfusion could be due to reduced loading of BDNF-pHluorin into vesicles. The increase in signal intensity during fusion was calculated to estimate the loading of BDNF-pHluorin into vesicles ([S1 Fig](#pbio.3000826.s004){ref-type="supplementary-material"}). In the 2 conditions, the fusion intensity was similar (WT = 1.494 ± 0.101; DKO = 1.519 ± 0.033; *p* = 0.748; [S2 Fig](#pbio.3000826.s005){ref-type="supplementary-material"}). Hence, CaMKII is not involved in the loading of neuropeptides into DCVs.

Taken together, our data demonstrate that CaMKII is a positive regulator of neuromodulation by promoting the number of available DCVs. Moreover, CaMKII is not involved in the fusion of SVs.

CaMKII DKO neurons have reduced number of DCVs per synapse {#sec005}
----------------------------------------------------------

Because the total number of BDNF-pHluorin-labeled DCVs was significantly reduced ([Fig 2B](#pbio.3000826.g002){ref-type="fig"}), we tested whether CaMKII regulates the expression of the reporter by regulating the promoter activity of the synapsin promoter in our reporter construct. Like many other studies, we designed these reporters to be specific for neurons and do not express in the supporting glia in the cultures, using the widely used (human) synapsin promoter. However, the expression levels of all constructs driven by this synapsin promoter were similar ([S2 Fig](#pbio.3000826.s005){ref-type="supplementary-material"}).

Second, to better characterize the effects of CaMKII on the number of DCVs, neurons were immunostained for a series of endogenous and exogenous DCV markers ([Fig 3A--3D](#pbio.3000826.g003){ref-type="fig"}). Both endogenous BDNF (WT = 0.920 ± 0.144; DKO = 0.535 ± 0.107; *p* = 5.54 × 10^−4^; [Fig 3B](#pbio.3000826.g003){ref-type="fig"}) and Chromogranin B (CHGB) (WT = 0.895 ± 0.188; DKO = 0.421 ± 0.077; *p =* 2.53 × 10^−7^; [Fig 3C](#pbio.3000826.g003){ref-type="fig"}), and exogenous neuropeptide Y (NPY) pHluorin (WT = 1.023 ± 0.130; DKO = 0.446 ± 0.094; *p =* 8.41 × 10^−7^; [Fig 3D](#pbio.3000826.g003){ref-type="fig"}) levels were severely reduced at synapses. Because the loading of neuropeptides into vesicles was unchanged in DKO neuron ([S1 Fig](#pbio.3000826.s004){ref-type="supplementary-material"}), these data indicate that the average number of DCVs at synapses was reduced in the absence of CaMKII.

![CaMKII controls the abundance of DCVs, not SVs or secretory machinery.\
(A) Schematic representation of the immunostaining of DCV markers, in color. (B) Left, typical images of neurites of WT (left) and DKO (right) immunostained for BDNF. Right, quantification of BDNF intensity at VGLUT1 labeled synapses in WT and DKO neurons. (C) Left, typical images of neurites of WT (left) and DKO (right) immunostained for CHGB. Right, quantification of CHGB intensity at VGLUT1 labeled synapses in WT and DKO neurons. (D) Left, typical images of neurites of WT (left) and DKO (right) immunostained for the exogenous DCV marker NPY-pHluorin. Right, quantification of NPY-pHluorin intensity at VGLUT1 labeled synapses in WT and DKO neurons. (E) Schematic representation of the immunostaining of SV markers, in color. (F) Left, typical images of neurites of WT (left) and DKO (right) immunostained for VGLUT1. Right, quantification of VGLUT1 intensity in WT and DKO neurons. (G) Left, typical images of neurites of WT (left) and DKO (right) immunostained for VAMP2. Right, quantification of VAMP2 intensity at VGLUT1-labeled synapses in WT and DKO neurons. (H) Left, typical images of neurites of WT (left) and DKO (right) immunostained for Syn1. Right, quantification of Syn1 intensity at VGLUT1 labeled synapses in WT and DKO neurons. (I) Schematic representation of the immunostaining of exocytic proteins, in color. (J) Left, typical images of neurites of WT (left) and DKO (right) immunostained MUNC18. Right, quantification of MUNC18 intensity at VGLUT1-labeled synapses in WT and DKO neurons. (K) Left, typical images of neurites of WT (left) and DKO (right) immunostained for SNAP25. Right, quantification of SNAP25 intensity at VGLUT1 labeled synapses in WT and DKO neurons. (L) Left, typical images of neurites of WT (left) and DKO (right) immunostained for Syt1. Right, quantification of Syt1 intensity at VGLUT1-labeled synapses in WT and DKO neurons. Boxplots with 95% CI whiskers, white cross shows mean ± SEM, central bar is median. Columns and dots represent individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p \<* 0.05, \*\**p \<* 0.01, \*\*\**p \<* 0.001. Scale bar = 5 μm. CaMKII, Ca2+/calmodulin-dependent kinase II; CI, confidence interval; DCV, dense-core vesicle; DKO, double-knockout; MUNC18, mammalian uncoordinated 18; NPY, neuropeptide Y; n. s., not significant; SNAP25, synaptosomal-associated protein 25; SV, synaptic vesicle; Syn1, synapsin 1; VAMP2, vesicle-associated membrane protein 2; VGLUT1, vesicular glutamate transporter 1; WT.](pbio.3000826.g003){#pbio.3000826.g003}

To further investigate the lower neuromodulator levels in CaMKII DKO neurons, the number of DCVs was assessed along the neuritic arborization and stainings for endogenous neuromodulators were quantified as a function of the distance from the soma. The number of DCVs along the neuritic arborization was lower in CaMKII-deficient neurites ([S2 Fig](#pbio.3000826.s005){ref-type="supplementary-material"}), and the staining intensity was reduced in CaMKII DKO neurons at every point in the dendritic arborization ([S3 Fig](#pbio.3000826.s006){ref-type="supplementary-material"}). These data support our previous conclusion that CaMKII-deficient neurons contain fewer DCVs and, consequently, less neuromodulators in their neuritis. This suggests that the reduction in neuromodulator in CaMKII DKO neurons is explained by defects upstream of neurite targeting.

To evaluate whether this reduction is specific for DCVs, we analyzed the signal intensity of the SV markers vesicular glutamate transporter 1 (VGLUT1) ([Fig 3F](#pbio.3000826.g003){ref-type="fig"}), Synaptobrevin 2 (vesicle-associated membrane protein 2 \[VAMP2\]) ([Fig 3G](#pbio.3000826.g003){ref-type="fig"}) and Synapsin 1 (Syn1) ([Fig 3H](#pbio.3000826.g003){ref-type="fig"}). The levels of endogenous VGLUT1 and Syn1 were unaltered in the 2 conditions, in line with the SypHy ([S1 Fig](#pbio.3000826.s004){ref-type="supplementary-material"}) and Synapsin-mCherry data ([S2 Fig](#pbio.3000826.s005){ref-type="supplementary-material"}). We observed a minor reduction in the levels of VAMP2 (WT = 0.985 ± 0.087; DKO = 0.768 ± 0.129; *p* = 0.009). Moreover, in CaMKII-deficient synapses, the levels of mammalian uncoordinated (UNC) 18 (MUNC18-1) (WT = 0.941 ± 0.098; DKO = 0.656 ± 0.104; *p* = 7.65 × 10^−5^; [Fig 3J](#pbio.3000826.g003){ref-type="fig"}) and synaptosomal-associated protein 25 (SNAP25) (WT = 0.929 ± 0.114; DKO = 0.712 ± 0.088; *p =* 0.0017; [Fig 3K](#pbio.3000826.g003){ref-type="fig"}) were also decreased, whereas Synaptotagmin1 (Syt1) ([Fig 3L](#pbio.3000826.g003){ref-type="fig"}) was unaltered. These changes in VAMP2, MUNC18, and SNAP25 levels do not result in reduced SV fusion ([S2 Fig](#pbio.3000826.s005){ref-type="supplementary-material"}) nor to reduced synaptic transmission in brain slices of CaMKII DKO mice \[[@pbio.3000826.ref035]\]. These findings suggest that CaMKII has a minor role in regulating the accumulation of SV-associated and exocytic proteins.

We then reasoned that the combined effect of CaMKII loss and neurotrophin reduction could lead to morphological defects. It is known that CaMKII limits dendritic arborization by regulating Rem2-GTPase activity and by regulating ubiquitin signaling to the centrosome \[[@pbio.3000826.ref041], [@pbio.3000826.ref042]\]. Indeed, dendrite length was increased in CaMKII DKO neurons (WT = 4.83 ± 0.7 mm; DKO = 7.036 ± 0.958 mm; *p* = 0.00115; [S4 Fig](#pbio.3000826.s007){ref-type="supplementary-material"}). Surprisingly, the axonal length of DKO neurons was also increased (WT = 13.46 ± 3.02 mm; DKO = 23.52 ± 3.37 mm; *p* = 0.00248; [S4 Fig](#pbio.3000826.s007){ref-type="supplementary-material"}), contrary to what was previously reported in *Drosophila* larvae \[[@pbio.3000826.ref043]\]. The increase in neurite length was accompanied by an increased synapse density (WT = 25.5 ± 1.6 synapses per mm; DKO = 27.036 ± 0.958; *p* = 0.05; [S4 Fig](#pbio.3000826.s007){ref-type="supplementary-material"}). This indicates that CaMKII limits neurite growth and synaptogenesis in autaptic cultures.

These results indicate that CaMKII is required to maintain normal neuropeptide levels in synapses, as well as some members of the regulated secretory machinery, hence indirectly affecting neuropeptide secretion.

Fewer DCVs enter the axon of CaMKII DKO neurons, whereas DCV trafficking is unaffected {#sec006}
--------------------------------------------------------------------------------------

To evaluate whether the reduced neuropeptide levels at synapses is a consequence of a decreased loading of neuropeptides into DCVs or a decreased number of DCVs entering the axon, hippocampal neurons expressing BDNF-mCherry and the axon initial segment (AIS) marker voltage-gated sodium channel intracellular domain fused to blue fluorescent protein (BFP-NaV~II-III~) \[[@pbio.3000826.ref044]\] ([Fig 4A](#pbio.3000826.g004){ref-type="fig"}) were photobleached at the location of the AIS to visualize DCV trafficking into the axon ([Fig 4B](#pbio.3000826.g004){ref-type="fig"} and [S2 Movie](#pbio.3000826.s002){ref-type="supplementary-material"}). The number of BDNF-labeled vesicles trafficking into the AIS in CaMKII DKO neurons was reduced by 42% (WT = 4.115 ± 0.257 DCV per minute; DKO 2.395 ± 0.171; *p* = 1.52 × 10^−7^; [Fig 4C](#pbio.3000826.g004){ref-type="fig"}), in line with the reduction in intensity levels of endogenous BDNF and CHGB at synapses. To test whether the decreased number of trafficking DCVs was specific for the axon, 2 dendritic regions proximal to the soma were photobleached ([Fig 4E](#pbio.3000826.g004){ref-type="fig"}). The targeting of DCVs into dendrites was similar in WT and DKO neurons ([Fig 4F](#pbio.3000826.g004){ref-type="fig"}). The reduction in axonal targeting but normal dendritic targeting together leads to decreased axonal preference of DCV targeting (WT = 68.9 ± 0.05%; DKO = 60.6 ± 0.06; *p* = 0.0033; [Fig 4G](#pbio.3000826.g004){ref-type="fig"}). In addition, the number of BDNF-labeled DCVs traveling in a retrograde direction was increased by 35% (WT = 1.5 ± 0.29 DCV per minute; DKO = 2.0 ± 0.43; *p* = 0.0155; [S5 Fig](#pbio.3000826.s008){ref-type="supplementary-material"}) in DKO neurons. Further analysis on the run length and pausing time of DCVs at the AIS did not show any difference between WT and CaMKII DKO neuron ([S5 Fig](#pbio.3000826.s008){ref-type="supplementary-material"}), suggesting that the once the DCVs are loaded to the microtubles, their trafficking is CaMKII independent.

![CaMKII regulates the number of DCVs entering the axon but not their trafficking properties.\
(A) Schematic representation of AIS targeting; Na~v~II-III BFP was used to visualize the region of the AIS. BDNF-mCherry vesicles were bleached at the AIS to allow quantification of new vesicles entering the axon. (B) Left, typical example of AIS (top) with BDNF-mCherry-labeled DCVs before bleaching, after bleaching, and at the end of the recovery (top to bottom). Right, kymograph showing DCVs in the AIS after bleaching. (C) Quantification of DCV flux at the AIS calculated as the number of BDNF-mCherry positive puncta that enter the Na~v~II-III BFP area per minute in anterograde (from the soma to the axon) direction. (D) Quantification of BDNF-mCherry speed at the AIS in the anterograde direction. (E) Kymograph showing DCVs in proximal dendrites after bleaching. (F) Quantification of DCV flux in the proximal dendrites in the anterograde direction. (G) Axonal preference of DCV targeting, calculated as BDNF-mCherry-positive puncta entering in the Na~v~II-III BFP area in anterograde direction divided by the total number of BDNF-mCherry positive puncta exiting the soma. (H) Typical examples of axons labeled with mGFP showing NPY-mCherry labeled DCVs; kymographs represent axonal trafficking of NPY-mCherry in anterograde (solid lines) and retrograde (dashed lines) direction. Neurons were stimulated with 16 trains of 50 APs at 50 Hz (light blue bars). DCV speed was calculated before stimulation (B), during stimulation (S), and during recovery (R). (I) Ridgelines representing the density function of NPY-mCherry puncta speed along the axon, showing the characteristic differences in speed for anterograde and retrograde (filled and dashed density respectively) and the lower speed during stimulation. (J) Pie charts for WT (black) and DKO neurons (red) with the fraction of vesicles that stopped during stimulation (Stop), decreased their speed (Decrease), increased their speed (Increase), and maintained the same average speed (Maintain). (K) Schematic representation of DCV fusion assay. DCVs are labeled with NPY-mCherry, neurons are stimulated with 16 trains of 50 APs at 50 Hz (light blue bars). Individual DCV fusion events were quantified manually as puncta that suddenly lost their fluorescence signal. (L) Typical neurons labeled with mGFP overlaid with NPY-mCherry-labeled DCV fusion events (green dots). Axons were identified by the lack of spines. (M) Quantification of NPY-mCherry release fraction upon stimulation. (N) Quantification of the percentage of NPY-mCherry fusion events at axons. Boxplots with 95% CI whiskers, white cross shows mean ± SEM, and central bar is median. Columns and dots represent individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. Scale bar = 5 μm (B for still frames), 10 μm (B kymograph and E), 25 μm (H), 25 μm (L). AIS, axon initial segment; AP, action potential; BDNF, brain-derived neurotrophic factor; BFP, blue fluorescence protein; CaMKII, Ca2+/calmodulin-dependent kinase II; CI, confidence interval; DCV, dense-core vesicle; DKO, double-knockout; mGFP, membrane-bound green fluorescence protein; Nav~II-III~,voltage-gated sodium channel intracellular domain; NPY, neuropeptide Y; n. s., not significant; WT, wild type.](pbio.3000826.g004){#pbio.3000826.g004}

Extracellular, released BDNF is known to be transported to the soma when associated with tyrosine receptor B (TrkB) and subsequently internalized \[[@pbio.3000826.ref045]\]. We observed that CaMKII DKO neurons have increased TrkB internalization (WT = 77.0 ± 5.3 puncta per mm; DKO = 84.5 ± 3.8; *p* = 0.037; [S5 Fig](#pbio.3000826.s008){ref-type="supplementary-material"}); however, extracellular TrkB intensity, as well as extracellular transferrin receptor (TrfR), was unaltered in CaMKII DKO neurons compared with WT neurons ([S5 Fig](#pbio.3000826.s008){ref-type="supplementary-material"}) indicating that, at steady state, there is no defect in trafficking and secretion of constitutive secreted vesicles. DCV trafficking speed in both anterograde ([Fig 4D](#pbio.3000826.g004){ref-type="fig"}) and retrograde ([S5 Fig](#pbio.3000826.s008){ref-type="supplementary-material"}) direction was on average 1 μm/s and similar between DKO and WT neurons. Hence, CaMKII regulates neuropeptide content in synapses by facilitating the transport from the soma into the axon of hippocampal neurons.

In *Drosophila* NMJ, CaMKII regulates DCV mobilization and capture at synapses \[[@pbio.3000826.ref007], [@pbio.3000826.ref008]\]. Mammalian DCVs stall during high-frequency stimulation \[[@pbio.3000826.ref046]\], a process that might involve a CaMKII-dependent modification of the cargo-kinesins (KIFs) complex, like for the interaction of Mint1 and KIF17 \[[@pbio.3000826.ref023]\]. To evaluate this, we used high-density hippocampal cultures with 5% of neurons expressing tetracycling inducible (TetON) membrane-bound green fluorescence protein (mGFP) and NPY-mCherry. This allowed for discrimination between axon and dendrites to study DCV trafficking in both compartments ([Fig 4H](#pbio.3000826.g004){ref-type="fig"} and [S3 Movie](#pbio.3000826.s003){ref-type="supplementary-material"}). DCV speed was measured during high-frequency stimulation of 16 repetitions of 1-second field stimulation at 50 Hz and compared with speed during baseline (30 seconds before stimulation). The speed of moving DCVs was reduced during stimulation ([Fig 4I](#pbio.3000826.g004){ref-type="fig"}) for approximately 40% of vesicles in both anterograde and retrograde direction in both genotypes ([S5 Fig](#pbio.3000826.s008){ref-type="supplementary-material"}). The fraction of vesicles that stalled (speed reduced to zero) was 16%--18%, whereas 24%--29% increased their speed during stimulation, similar in both genotypes ([Fig 4J](#pbio.3000826.g004){ref-type="fig"}). Therefore, CaMKII promotes the axonal targeting of DCVs. However, CaMKII is dispensable for a normal trafficking and stimulation-dependent arrest of trafficking vesicles in the axon.

In cultured hippocampal neurons, DCV fusion occurs predominantly in the axon \[[@pbio.3000826.ref006]\]. To test whether this preference is altered in CaMKII DKO neurons, the location of DCV fusion ([Fig 4K](#pbio.3000826.g004){ref-type="fig"}) was quantified in the same sparse infected neurons ([Fig 4L](#pbio.3000826.g004){ref-type="fig"}). The total release fraction of NPY-mCherry-labeled DCVs was the same between the 2 groups ([Fig 4M](#pbio.3000826.g004){ref-type="fig"}). However, the percentage of fusion that occurred in axons of αβCaMKII-deficient neurons was reduced by 22% (WT = 85.09 ± 5.39%; DKO = 66.67 ± 13.25%; *p* = 0.0239; [Fig 4N](#pbio.3000826.g004){ref-type="fig"}).

Together, these results show that CaMKII regulates the number of DCVs entering the axon and axonal preference of DCV fusion but not DCV trafficking properties.

CaMKII regulates neuromodulator expression {#sec007}
------------------------------------------

The reduction of axonal preference for DCVs in CaMKII DKO neurons might be due to miss-targeting into dendrites or a general reduction in neuropeptide expression, thus reducing DCV number. Of the 4 BDNF transcripts \[[@pbio.3000826.ref030], [@pbio.3000826.ref047]\], transcript II and IV are regulated by low neuronal activity in a synergetic activity between CaMKII and PKC, via pCREB \[[@pbio.3000826.ref028]\]. CREB binding sites are also present in the promoters of CHGB \[[@pbio.3000826.ref048]\] and secretogranin2 (SCG2) \[[@pbio.3000826.ref049]\]. Therefore, we reasoned that in our culture system CaMKII regulates transcription of neuropeptide mRNAs ([Fig 5A and 5B](#pbio.3000826.g005){ref-type="fig"}).

![CaMKII regulates neuropeptide expression.\
(A) Representation of BDNF genomic locus, exons are shown as white boxes, the gray box represents the conserved exon shared between the different transcripts. (B) Quantification of mRNA fold change, expressed as ΔC~t~ values normalized to WT, showing the reduction of mRNA levels for CHGB, SCG2, and BDNF transcript 2 in DKO neurons compared with DKO neurons rescued with α and βCaMKII. BDNF transcript 4 is not affected by the lack of CaMKII. (C) Western blot showing the DCV cargo proteins CHGB (top) and SCG2 (bottom) in WT, DKO, and DKO-expressing αCaMKII or βCaMKII neurons. Actin was used as loading control. (D) Quantification of CHGB levels normalized to WT. (E) Quantification of SCG2 levels normalized to WT. Boxplots with 95% CI whiskers, white cross shows mean ± SEM, and central bar is the median. Columns and dots represent individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}; original Western blot can be found in S1 Raw images. ATG, transcription starting codon; BDNF, brain-derived neurotrophic factor; CaMKII, Ca2+/calmodulin-dependent kinase II; CHGB, chromogranin B; CI, confidence interval; DCV, dense-core vesicle; DKO, double-knockout; LTP, long-term potentiation; SCG2, secretogranin2; WT, wild type.](pbio.3000826.g005){#pbio.3000826.g005}

The mRNA levels of CHGB, SCG2, and BDNF transcript II (BDNF2) were significantly lower compared with WT (CHGB = 58%, SCG2 = 61%, BDNF2 = 50%; [Fig 5B](#pbio.3000826.g005){ref-type="fig"}). BDNF transcript IV, on the other hand, was not significantly reduced (BDNF4 = 70%) yet was lower than WT levels. Expression of all transcripts was rescued by simultaneously overexpressing α and βCaMKII. Hence, in cultured hippocampal neurons, CaMKII regulates the transcription levels of DCVs cargos.

To evaluate that reduced transcription leads to the decreased axonal preference by reduced protein levels, we quantified total cellular protein levels by Western blot ([Fig 5C](#pbio.3000826.g005){ref-type="fig"}) of the DCV markers CHGB and SCG2. The expression of both proteins was decreased in DKO neurons compared with WT neurons; CHGB levels were reduced to 60% of WT ([Fig 5D](#pbio.3000826.g005){ref-type="fig"}) and SCG2 to 76% ([Fig 5E](#pbio.3000826.g005){ref-type="fig"}). CaMKII holoenzymes are multimers of α and β subunits and the action of the 2 subunits is interdependent, e.g., βCaMKII KO neurons have substantial impairments in αCaMKII signaling, resembling αCaMKII KO \[[@pbio.3000826.ref021]\]. Therefore, we overexpressed the individual subunits in the DKO background to test if either α- or βCaMKII has a dominant function in regulating neuropeptide levels in hippocampal neurons. αCaMKII did not restore neuropeptide levels, whereas βCaMKII restored expression levels to 70% and 95%, respectively, for CHGB and SCG2. Thus, βCaMKII regulates the transcription of neuromodulators, and the absence of the β gene is responsible for the reduction in the amount of neuromodulators produced.

Secreted BDNF and CaMKII are required for BDNF-induced neuromodulator expression {#sec008}
--------------------------------------------------------------------------------

BDNF is known to enhance transcription of neuropeptides and neuromodulators \[[@pbio.3000826.ref050]--[@pbio.3000826.ref052]\], including the precursor of BDNF itself \[[@pbio.3000826.ref053]--[@pbio.3000826.ref055]\]. In addition, extracellular, secreted BDNF is known to activate CaMKII via its receptor TrkB \[[@pbio.3000826.ref056]\]. We therefore hypothesized that BDNF-dependent activation of CaMKII is required for a normal neuromodulator expression. To test this, BDNF was scavenged from the culture medium by adding 0.2 μg/ml of BDNF antibody (BDNF Ab) \[[@pbio.3000826.ref057]\] at DIV 15 and DIV 16 and analyzed BDNF-induced BDNF expression. As a control, 100 ng/ml of recombinant BDNF \[[@pbio.3000826.ref058]\] was added at the same DIVs ([Fig 6A](#pbio.3000826.g006){ref-type="fig"}). To avoid cross-contamination of the antibody and the recombinant BDNF, proBDNF was used for the quantification of CaMKII-dependent BDNF expression ([Fig 6B](#pbio.3000826.g006){ref-type="fig"}). As expected, somatic proBDNF levels were reduced in CaMKII DKO neurons compared with WT neurons (WT = 1 ± 0.064; DKO = 0.768 ± 0.039; *p* = 9.35 × 10^−3^; [Fig 6C](#pbio.3000826.g006){ref-type="fig"}), in line with the reduced BDNF levels in synapses of DKO neurons ([Fig 3B](#pbio.3000826.g003){ref-type="fig"}). When BDNF was scavenged, the levels of proBDNF in WT somas decreased to the same levels (WT = 0.847 ± 0.051; DKO = 0.804 ± 0.038; *p* = 0.371; [Fig 6C](#pbio.3000826.g006){ref-type="fig"}). Conversely, addition of BDNF increased the levels of somatic proBDNF in WT but not in DKO neurons (WT = 1.071 ± 0.052; DKO = 0.819 ± 0.05; *p* = 9.46 × 10^−5^; [Fig 6C](#pbio.3000826.g006){ref-type="fig"}). This indicates that CaMKII is required for BDNF-induced (pro)BDNF expression.

![Secreted BDNF is sufficient to increase BDNF levels in the presence of CaMKII.\
(A) Schematic representation of the experimental design, 0.2 μg/ml of BDNF Ab or 100 ng/ml of recombinant BDNF were added every 24 hours for 2 days before fixing the neurons and immunostained for proBDNF. (B) Typical examples of proBDNF in the soma from untreated neurons (Naive), treated with BDNF Ab or BDNF. (C) Quantification of somatic proBDNF intensity normalized to WT (dash line). (D) Schematic representation of the experimental design, lentiviral particles containing TeNT, which is responsible to cleaved VAMP1-3 (hence, inhibiting SV and DCV fusion), were added 6 DIVs before fixing the neurons and immunostained for BDNF. (E) Typical examples of BDNF in synapses from untreated (Naive) cells or treated with TeNT. (F) Quantification of synaptic BDNF intensity normalized to WT (dash line). Boxplots with 95% CI whiskers, white cross shows mean ± SEM. Columns and dots represents individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. Scale bar = 20 μm (B-E). BDNF, brain-derived neurotrophic factor; BDNF-Ab, BDNF antibody; CaMKII, Ca2+/calmodulin-dependent kinase II; CI, confidence interval; DCV, dense-core vesicle; DIV, day in vitro; DKO, double-knockout; SV, synaptic vesicle; TeNT, tetanus neurotoxin; VAMP, vesicle-associated membrane protein; WT, wild type.](pbio.3000826.g006){#pbio.3000826.g006}

To test whether BDNF-induced proBDNF expression involves the soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor (SNARE)-dependent BDNF secretion from the neurons themselves, cultures were infected with tetanus neurotoxin (TeNT), which cleaves vesicle-associated membrane protein (VAMP) 1--3 and blocks fusion of SVs and DCVs \[[@pbio.3000826.ref059]\], at DIV 11 ([Fig 6D](#pbio.3000826.g006){ref-type="fig"}). After 6 DIVs of TeNT expression, BDNF levels in synapses of WT neurons were reduced drastically ([Fig 6E](#pbio.3000826.g006){ref-type="fig"}), comparable with untreated CaMKII DKO neurons (WT naive = 1 ± 0.083; DKO Naive = 0.599 ± 0.035; WT TeNT = 0.66 ± 0.05; DKO TeNT = 0.71 ± 0.06; Kruskal--Wallis Χ^2^ \[3,115\] = 0.0002, [Fig 6F](#pbio.3000826.g006){ref-type="fig"}). TeNT expression in CaMKII DKO cultures, on the other hand, did not alter the levels of synaptic BDNF. These data indicate that secreted BDNF requires CaMKII to increase neuromodulator expression.

CaMKII is required for BDNF-induced BDNF accumulation via pCREB {#sec009}
---------------------------------------------------------------

In addition to activating CaMKII \[[@pbio.3000826.ref056]\], BDNF is known to increase pCREB at S133 \[[@pbio.3000826.ref060]\]. CaMKII regulates gene expression by a signal cascade that involves pCREB at S133 \[[@pbio.3000826.ref027], [@pbio.3000826.ref061], [@pbio.3000826.ref062]\]. Thus, we tested the hypothesis that altering downstream targets of CaMKII in the signal cascade toward pCREB restores BDNF levels in neurons lacking CaMKII.

First, we compared pCREB levels in resting WT and CaMKII DKO neurons. Using a Ser133-specific antibody, we observed that pCREB levels were 40% lower in DKO neurons (WT = 1 ± 0.11; DKO = 0.6 ± 0.05; *p* = 1.5 × 10^−3^ [Fig 7A and 7B](#pbio.3000826.g007){ref-type="fig"}). Second, we tested whether overexpression of 3 components in the signal cascade between CaMKII and pCREB restored a normal pCREB level in DKO neurons. The reduced pCREB levels were restored by addition of CaMKIV (WT = 1.169 ± 0.091; DKO = 1.082 ± 0.088; *p* = 0.116 [Fig 7B](#pbio.3000826.g007){ref-type="fig"}), nuclear-localized neurogranin (NLS-Nrgn), which targets CaM to the nucleus and release it upon Ca^2+^ influx \[[@pbio.3000826.ref027]\] (WT = 1.4 ± 0.09; DKO = 1.24 ± 0.1; *p* = 0.083 [Fig 7B](#pbio.3000826.g007){ref-type="fig"}), and a CREB mutation that lowers the threshold for S133 phosphorylation by PKA (Y134F) \[[@pbio.3000826.ref063]\] (WT = 4.047 ± 0.568; DKO = 1.908 ± 0.271; *p* = 0.002 [Fig 7B](#pbio.3000826.g007){ref-type="fig"}). Together, these data confirm that also in our system, CaMKII is required for normal pCREB levels and that overexpression of previously implicated components of the signal cascade between CaMKII and CREB restores a normal pCREB level in CaMKII DKO neurons.

![CaMKII is required for BDNF-induced BDNF production via pCREB.\
(A) Typical example of nuclei immunostained for pCREB at Ser-133. (B) Quantification of pCREB signal intensity normalized to WT (dashed line). (C) Typical examples of BDNF in synapses from untreated (Naive) cells, or treated with CaMKIV, NLS-Nrgn, or CREB-Y134F. (D) Quantification of synaptic BDNF intensity normalized to WT. (E) Typical examples of proBDNF in the soma from untreated neurons (Naive), treated NLS-Nrgn or CREB-Y134F. (F) Quantification of somatic proBDNF intensity normalized to WT (dash line). Boxplots with 95% CI whiskers, white cross shows mean ± SEM. Columns and dots represents 0individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p \<* 0.001. Scale bar = 20 μm (A-E) and 10 μm (C). BDNF, brain-derived neurotrophic factor; CaMKII, Ca2+/calmodulin-dependent kinase II; CaMKIV, Ca2+/calmodulin-dependent kinase IV; CREB, cAMP-response element binding protein; CREB-Y134F, phosphorylation of CREB with Tyr-to-Phe substitution at position 134; DKO, double-knockout; NLS-Nrgn, nuclear-localized neurogranin; n.s., not significant; pCREB, CREB phosphorylation; WT, wild type.](pbio.3000826.g007){#pbio.3000826.g007}

We then tested if these components of the signal cascade between CaMKII and CREB also restore the reduced BDNF levels in CaMKII DKO synapses, using a phospho-dead mutant of CREB, with Ser-to-Ala substitution at position 133 (CREB-S133A) \[[@pbio.3000826.ref064]\] as a negative control. Indeed, the lower synaptic BDNF staining was fully restored upon overexpression of CaMKIV, NLS-Nrgn, and phosphorylation of CREB with Tyr-to-Phe substitution at position 134 (CREB-Y134F) (naive: WT = 1 ± 0.1; DKO 0.63 ± 0.04, *p* = 0.0078; CaMKIV: WT = 1 ± 0.06; DKO 0.94 ± 0.11, *p* = 0.077; NLS-Nrgn: WT = 1 ± 0.08; DKO 1.24 ± 0.15, *p* = 0.304; CREB-Y134F: WT = 1 ± 0.08; DKO 1.018 ± 0.137, *p* = 0.2 [Fig 7C and 7D](#pbio.3000826.g007){ref-type="fig"}). Expression of CREB-S133A led to reduced pCREB in unstimulated neurons, as expected \[[@pbio.3000826.ref064]\] ([S6 Fig](#pbio.3000826.s009){ref-type="supplementary-material"}), and BDNF levels were not restored in CaMKII DKO synapses (WT = 1 ± 0.08; DKO = 0.52 ± 0.05; *p* = 4.88 × 10^−5^ [S6 Fig](#pbio.3000826.s009){ref-type="supplementary-material"}). Together these data suggest that CaMKII regulates neuromodulation and synaptic BDNF levels via a signal cascade that involves calmodulin targeting to the nucleus, CaMKIV, and pCREB.

To confirm that the restored synaptic BDNF levels were due to new BDNF production, somatic proBDNF levels were also quantified after expression of NLS-Nrgn and CREBY134F ([Fig 7E](#pbio.3000826.g007){ref-type="fig"}). The expression of either construct did not alter proBDNF levels in WT neurons. However, both restored the levels of proBDNF in DKO neurons (naive: WT = 1 ± 0.06, DKO 0.85 ± 0.05, *p* = 0.0122; NLS-Nrgn: WT = 1.089 ± 0.093, DKO 0.951 ± 0.13, *p* = 0.304; CREB-Y134F: WT = 1.982 ± 0.087, DKO 1.323 ± 0.098, *p* = 2 × 10^−4^ [Fig 7F](#pbio.3000826.g007){ref-type="fig"}). Altogether, these data suggest that CaMKII is a critical factor in a positive feedback loop between secreted neuromodulators, such as BDNF, and the induction of the expression of their precursors via a CaMKII-mediated signal cascade that involves CaMKIV and pCREB.

βCaMKII activity regulates neuropeptide levels {#sec010}
----------------------------------------------

Because βCaMKII is known to be the dominant paralog to enhance pCREB \[[@pbio.3000826.ref027]\] and βCaMKII, but not αCaMKII, rescued the total amount of CHGB and SCG2 ([Fig 5D and 5E](#pbio.3000826.g005){ref-type="fig"}), we hypothesized that βCaMKII is necessary and sufficient for the regulation of neuropeptide expression and normal synaptic neuromodulator levels.

To test this hypothesis, we expressed α- and βCaMKII mutants that cannot be phosphorylated at their inhibitory sites, shown to cause a reduction in the threshold for LTP (long-active \[LA\], TT305/306VA for αCaMKII, and TT306/307VA for βCaMKII) \[[@pbio.3000826.ref065], [@pbio.3000826.ref066]\], or a kinase-dead (\[KD\] K42R for αCaMKII and K43R for βCaMKII) mutation \[[@pbio.3000826.ref067]\] ([Fig 8A](#pbio.3000826.g008){ref-type="fig"}) in CaMKII DKO neurons and immunostained them for the DCVs marker CHGB ([Fig 8B](#pbio.3000826.g008){ref-type="fig"}) and endogenous BDNF ([Fig 8C](#pbio.3000826.g008){ref-type="fig"}). Compared with mock infected DKO neurons, DKO neurons expressing βCaMKII-LA had increased levels of both CHGB (WT = 1 ± 0.08; DKO = 0.73 ± 0.05; α = 0.76 ± 0.1; αLA = 0.7 ± 0.07; αKD = 0.7 ± 0.08; β = 1.1 ± 0.15; βLA = 0.98 ± 0.13; βKD = 0.71 ± 0.07; Kruskal--Wallis Χ^2^\[7,231\] = 0.0282 [Fig 8B](#pbio.3000826.g008){ref-type="fig"}) and BDNF (WT = 1 ± 0.1; DKO = 0.52 ± 0.04; α = 0.52 ± 0.04; αLA = 0.57 ± 0.04; αKD = 0.63 ± 0.06; β = 0.63 ± 0.07; βLA = 0.84 ± 0.39; βKD = 0.6 ± 0.04; Kruskal--Wallis Χ^2^(7,231) = 6.38 × 10^−5^ [Fig 8C](#pbio.3000826.g008){ref-type="fig"}). These levels were similar to WT cells. For CHGB, βCaMKII-WT rescued the immunoreactivity ([Fig 8B](#pbio.3000826.g008){ref-type="fig"}), as suggested by the Western blot data ([Fig 5D](#pbio.3000826.g005){ref-type="fig"}). The KD variant of βCaMKII did not rescue the reduced BDNF or CHGB immunoreactivity. These data confirm that βCaMKII has an important enzymatic function to regulate synaptic levels of neuropeptides and neurotrophic factors.

![CaMKII activity controls neuropeptide levels.\
β (A) Schematic representation of WT αCaMKII (left) with Ca/CaM-induced autophosphorylation of T286 triggering the activity of the kinase. The TT305/306VA mutation (middle) inhibits TT305/6 inhibitory phosphorylation leading to an LA form of the kinase. The K42R mutation (right) does not allow T286 autophosphorylation producing a KD CaMKII. For βCaMKII, the mutations are TT306/307VA and K43R for the LA and KD, respectively. (B) Top, typical neurites immunostained for the endogenous DCV marker CHGB; bottom, quantification of synaptic CHGB intensity levels at VGLUT1 positive synapses for DKO and DKO rescued with the indicated constructs normalized to WT. (C) Top, typical neurites immunostained for endogenous BDNF; bottom, quantification of synaptic BDNF intensity levels at VGLUT1 positive synapses for DKO and DKO rescued with the indicated constructs normalized to WT. (D) Schematic representation of the mechanism for CaMKII- and BDNF-dependent gene expression. BDNF binds to TrkB receptors; BDNF-TrkB binding leads to activation of βCaMKII that triggers a downstream pathway leading to Ca/CaM to enter into the nucleus and activating CaMKIV, which in turn phosphorylate CREB at S133. Neuropeptides and neuromodulator are then loaded into DCVs and targeted to dendrites and synapses, where they will fuse with the plasma membrane releasing their content. This mechanism will create a positive feedback loop to regulate neuromodulators content. Boxplots with 95% CI whiskers, white cross shows mean ± SEM. Columns and dots represents individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. Scale bar = 10 μm (B and D). Ca/CaM, Ca2+/Calmodulin; CaMKII, Ca2+/calmodulin-dependent kinase II; CaMKIV, Ca2+/calmodulin-dependent kinase IV; CHGB, chromogranin B; CI, confidence interval; CREB, cAMP-response element binding protein; DCV, dense-core vesicle; DKO, double-knockout; KD, kinase-dead; LA, long-active; NLS-Nrgn, nuclear-localized neurogranin; SV, synaptic vesicle; Syn1, synapsin1; TrKB, tyrosine receptor kinase B; VAMP2, vesicle-associated membrane protein 2; VGLUT1, vesicular glutamate transporter 1; WT, wild type.](pbio.3000826.g008){#pbio.3000826.g008}

The dendritic length was also normalized to WT levels with overexpression of the constitutively active form of βCaMKII ([S7 Fig](#pbio.3000826.s010){ref-type="supplementary-material"}), confirming its function in regulating dendritic arborization \[[@pbio.3000826.ref041], [@pbio.3000826.ref042]\], while synapse density was increased in all genotypes, except for the αCaMKII-LA ([S7 Fig](#pbio.3000826.s010){ref-type="supplementary-material"}), indicating that αCaMKII activity is required to limit synaptogenesis in primary hippocampal neurons.

Together, these data indicate that the kinase activity of βCaMKII is critical to regulating neuropeptide levels at synapses. Thus, βCaMKII serves as a central link for BDNF-induced neuromodulator production controlling the signaling cascade toward pCREB, whereas it is dispensable for the trafficking of neuromodulator containing DCVs and their fusion at synapses ([Fig 8D](#pbio.3000826.g008){ref-type="fig"}).

Discussion {#sec011}
==========

This study confirms that CaMKII regulates the secretion of neuromodulatory signals. However, the current data reveal that in mouse hippocampal neurons, the release machinery that drives this process operates at a typical efficiency in the absence of α- and βCaMKII. Instead, we discovered that fewer DCVs that contain these neuromodulators were targeted into the axon, leading to fewer DCVs per synapse and less neuromodulator secretion during/after stimulation. This reduced axonal targeting was specific for DCVs; targeting of SV markers and exocytic proteins was only marginally reduced. The reduction of axonal targeting was explained mainly by a reduction in neuromodulator expression. We show that CaMKII is a crucial component in a positive feedback loop activated by secreted BDNF that promotes neuromodulator expression via βCaMKII, CaMKIV and pCREB. Finally, the kinase activity of βCaMKII, but not αCaMKII, was essential for normal neuromodulator expression and targeting to the axon.

CaMKII was already implicated in neuromodulator secretion based on pharmacological perturbations in mouse \[[@pbio.3000826.ref010]\] and *Drosophila* \[[@pbio.3000826.ref007], [@pbio.3000826.ref008]\] and using genetic perturbation in *C*. *elegans* \[[@pbio.3000826.ref009]\]. However, these studies reached different conclusions, based on different assays: pharmacological inhibition reduced the amount of DCV marker fluorescence lost from dendrites \[[@pbio.3000826.ref010]\] or NMJ buttons \[[@pbio.3000826.ref007]\] during stimulation, which was interpreted as reduced neuromodulator secretion. In contrast, mutant nematodes showed reduced DCV marker fluorescence in axons but a typical accumulation in coelomocytes, which was interpreted as abnormal DCV targeting but normal secretion \[[@pbio.3000826.ref009]\]. Our study provides the first data that directly assess DCV fusion, at single vesicles' resolution, demonstrating that CaMKII is not required for the fusion process itself and thus agrees with the nematode study. Hence, pharmacological and genetic perturbations appear to result in different conclusions. The use of chemical inhibitors provides the most acute perturbations, but KN-93 is known to have side effects on the activity of other kinases and ion channel function \[[@pbio.3000826.ref068]\].

One of the well-characterized actions of CaMKII is to couple excitation to transcription of neuronal plasticity genes, such as BDNF, via pCREB \[[@pbio.3000826.ref025]--[@pbio.3000826.ref027], [@pbio.3000826.ref069]\]. Pharmacological inhibition of CaMKII represses the chromatin state of BDNF promoter \[[@pbio.3000826.ref070]\] and blocks long-term depression (LTD)-mediated BDNF transcription \[[@pbio.3000826.ref028]\]. Likewise, CHGB \[[@pbio.3000826.ref048]\] and SCG2 \[[@pbio.3000826.ref049]\] genes contain a CREB binding site, and their expression in PC12 cells is activity dependent \[[@pbio.3000826.ref071]\]. In this study, we observed that the mRNA levels of CHGB, SCG2, and BDNF transcript II were also reduced, resulting in a reduced protein level of these DCV cargos, whereas a less activity-sensitive transcript of BDNF (transcript IV) \[[@pbio.3000826.ref028], [@pbio.3000826.ref030]\] was not reduced. Our data indicate that active βCaMKII expression restores CHGB and SCG2 protein levels ([Fig 5D and 5E](#pbio.3000826.g005){ref-type="fig"}). βCaMKII selectively regulates excitation--translation coupling via CaMKIV-dependent pCREB \[[@pbio.3000826.ref027]\] and, unlike αCaMKII, is expressed in both glutamatergic and GABAergic neurons \[[@pbio.3000826.ref072]\]. Our study demonstrates that activating the signal cascade downstream of βCaMKII restores neuromodulator expression in a pCREB-dependent manner (Figs [7](#pbio.3000826.g007){ref-type="fig"} and [8](#pbio.3000826.g008){ref-type="fig"}). Therefore, we conclude that βCaMKII activity, but not αCaMKII activity, induces expression of neuromodulators and other DVC cargo by activating a downstream pathway involving nuclear translocation of CaM, CaMKIV activation, and pCREB ([Fig 8J](#pbio.3000826.g008){ref-type="fig"}).

Secreted neuromodulators like BDNF are known to activate CaMKII \[[@pbio.3000826.ref056]\]. Our study suggests that this BDNF-induced CaMKII activity, especially βCaMKII activity, is part of a positive feedback loop to initiate a signal cascade that induces neuromodulator expression, e.g., to compensate for neuromodulators lost because of evoked secretion. Indeed, preventing BDNF secretion or scavenging of secreted BDNF in WT neurons produced a phenocopy of the situation in CaMKII DKO neurons ([Fig 6](#pbio.3000826.g006){ref-type="fig"}). In addition, expression of components of the signal cascade downstream of βCaMKII activation restored the levels of BDNF in CaMKII DKO synapses ([Fig 7](#pbio.3000826.g007){ref-type="fig"}). Thus, in addition with the well-established role of forming the holoenzyme together with αCaMKII and its targeting to the PSD \[[@pbio.3000826.ref021], [@pbio.3000826.ref022], [@pbio.3000826.ref035], [@pbio.3000826.ref069], [@pbio.3000826.ref072]\], βCaMKII has a unique role not shared by αCaMKII. In mouse hippocampal neurons, βCaMKII acts in a positive feedback loop downstream of BDNF binding to Trk receptors and upstream of CaMKIV-dependent pCREB, which supports normal neuromodulator secretion ([Fig 8](#pbio.3000826.g008){ref-type="fig"}).

Episomal expression of DCV cargo did not restore a normal amount of DCVs and BDNF at synapses. Hence, the availability of excess template is not sufficient to restore normal DCV/BDNF amounts. Although one such DCV cargo, e.g., BDNF/NPY, is overexpressed, expression of other DCV proteins that are also regulated by CaMKII, like CHGB, are most likely still reduced. This might prevent a normal DCV biogenesis rate, and the excess single overexpressed cargo might be subject to degradation.

Increasing pCREB restored normal levels of BDNF in DKO neurons but induced no further increase in WT neurons (Figs [6](#pbio.3000826.g006){ref-type="fig"} and [7](#pbio.3000826.g007){ref-type="fig"}). This seems in contrast with previous observations that at least mRNA levels increase in WT neurons after BDNF application \[[@pbio.3000826.ref053]--[@pbio.3000826.ref055]\]. First, as in many other cases, mRNA levels may simply not predict protein levels, because of extensive posttranslational regulation. For instance, episomal expression of DCV cargo did not restore a normal amount of DCVs and BDNF at synapses, and such episomally encoded cargo might be subject to degradation (see previous) Second, the regulation of BDNF mRNA levels is complex and may differ under different experimental conditions. For instance, in immature cortical neuronal cultures, BDNF mRNA is differentially regulated via a CaMKII-dependent and a mitogen-activated protein kinase (MAPK)-dependent pathway \[[@pbio.3000826.ref030], [@pbio.3000826.ref054], [@pbio.3000826.ref055]\]. The MAPK cascade, however, is not necessary to maintain normal BDNF mRNA transcription in unstimulated neurons \[[@pbio.3000826.ref055]\].

Although the secretion of neuromodulatory signals is affected in the absence of α- and βCaMKII, secretion of SVs at single synapses was normal ([S1A--S1F Fig](#pbio.3000826.s004){ref-type="supplementary-material"}) during high-frequency stimulation. These data are in line with previous studies in single null mutant neurons: at CA3 synapses, αCaMKII, or βCaMKII deficiency does not alter basal neurotransmission but abolishes LTP \[[@pbio.3000826.ref021], [@pbio.3000826.ref031]\]. In contrast, overexpression of α- or βCaMKII was shown to have opposite effects on spontaneous fusion of SVs in brain slices. The frequency of miniature excitatory postsynaptic current (mini-EPSC) was reduced in αCaMKII overexpression, whereas βCaMKII increased the frequency \[[@pbio.3000826.ref072]\]. Such effects, mainly the increased frequency, may be explained by CaMKII's role in neuromodulation, as increased BDNF secretion was reported to increase mini-EPSC frequency \[[@pbio.3000826.ref002]\]. Furthermore, we observed that dendritic and axonal length and synapse number were all increased in the absence of α- and βCaMKII ([S3 Fig](#pbio.3000826.s006){ref-type="supplementary-material"}). Such changes in synapse number are also expected to affect overall spontaneous SV fusion frequency.

Both CaMKII isoforms are required for LTP in the hippocampus \[[@pbio.3000826.ref021], [@pbio.3000826.ref065], [@pbio.3000826.ref073]\], and neuromodulators, especially BDNF, are too \[[@pbio.3000826.ref074]\]. The 40% reduction in DCV fusion events per cell ([Fig 1G](#pbio.3000826.g001){ref-type="fig"}) may help to link these 2 well-documented phenomena. However, the role of BDNF release in LTP is also demonstrated by acute pharmacological inhibition of CaMKII with KN-93, which strongly decreased the dendritic release of BDNF \[[@pbio.3000826.ref010]\]. This acute effect is unlikely to be explained by transcriptional regulation, as we report here for reduced BDNF release in our system. Hence, LTP probably involves additional KN-93 or CaMKII-dependent processes.

In *Drosophila* NMJ synapses, acute inhibition of CaMKII with KN-93 does not alter basal DCV fusion, but it limits the mobilization of stationary vesicles \[[@pbio.3000826.ref033]\] and the capture at synapses of DCVs transiting along the axon \[[@pbio.3000826.ref034]\]. This joint effect on mobilization and capture was proposed as a mechanism to support efficient DCV supply and fusion at NMJs during intense stimulation \[[@pbio.3000826.ref007], [@pbio.3000826.ref033]\]. Our data indicate that in mammalian neurons, the activity of CaMKII is dispensable for normal fusion efficiency. These mobilization and capture mechanisms may not be crucial in mammalian neurons, and they might be different between NMJ and CNS synapses or redundant mechanisms may have evolved to secure efficient fusion in the absence of α- and βCaMKII.

We observed that altered neuromodulation in the absence of CaMKII is explained by a robust and rather specific reduction of neuropeptides in synapses ([Fig 3](#pbio.3000826.g003){ref-type="fig"}). A similar phenotype was observed in *C*. *elegans* motor neurons, where DCV cargo was also reduced in axons \[[@pbio.3000826.ref009]\]. We observed that cargo loading in individual vesicles was unaltered ([S1G--S1I Fig](#pbio.3000826.s004){ref-type="supplementary-material"}), indicating that the reduction of neuropeptide levels at synapses must be attributed to fewer DCVs and not too less cargo per vesicle, in line with observations in *C*. *elegans* motoneurons \[[@pbio.3000826.ref009]\]. Interestingly, endogenous and exogenous DCV cargo was subject to the same reduction, suggesting that neuropeptide overexpression does not rescue the number of DCVs produced.

We observed that 50% fewer DCVs enter the axon of DKO neurons, whereas the same number entered into dendrites ([Fig 4A--4G](#pbio.3000826.g004){ref-type="fig"}). This observation cannot be explained by an altered neuromodulator expression and probably involves CaMKII targets other than CREB. The targeting of vesicles to specific compartments involves post-translational modification of both cytoskeletal \[[@pbio.3000826.ref075]\] and motor proteins \[[@pbio.3000826.ref076]\]. For instance, a mutation in the CaMKII substrate cyclin-dependent kinase 5 \[[@pbio.3000826.ref077]\] leads to the loss of neuropeptides targeting to the axon with a compensatory increase in dendritic targeting \[[@pbio.3000826.ref078]\]. However, we did not observe such compensation, indicating that the altered targeting observed in the current study differs from what was previously reported. Therefore, CaMKII regulates neuromodulation by promoting DCV targeting to axons, with a mechanism that appears to be independent from dendritic targeting.

We also observed an increased number of retrograde moving vesicles in the axon ([S3 Fig](#pbio.3000826.s006){ref-type="supplementary-material"}). This phenomenon could be a consequence of decreased synaptic capture of DCVs, which in *Drosophila* NMJ depends on CaMKII \[[@pbio.3000826.ref008]\]. In NMJ boutons, electrical activity causes a rapid reduction of GFP-labeled neuropeptide signal \[[@pbio.3000826.ref034]\]; this signal slowly recovers (25% recovery in 5 minutes) by capturing DCVs transiting along the axon in a process mediated by CaMKII activity \[[@pbio.3000826.ref008]\]. However, we did not observe differences in the trafficking properties of DCVs in DKO axons, neither in baseline transport nor after high-frequency stimulation, where most DCVs reduce speed and arrest \[[@pbio.3000826.ref046], [@pbio.3000826.ref079]\]. In dendrites, CaMKII is required to disrupt the interaction between KIF17 and Mint1, allowing cargo unloading from the motor complex \[[@pbio.3000826.ref023]\], and calmodulin was recently reported to regulate DCV-kinesin loading and unloading in dendritic spines \[[@pbio.3000826.ref080]\]. These considerations strengthen the idea that in addition to regulating neuromodulator expression, CaMKII also regulates DCV targeting to axons.

In conclusion, the current study provides direct evidence that CaMKII is dispensable for efficient neuromodulator exocytosis in mouse hippocampal neurons and that βCaMKII regulates neuromodulation by promoting CaMKIV-dependent neuropeptide expression downstream of BDNF signaling. Hence, CaMKII is crucial in a feedback loop coupling neuromodulator secretion to neuromodulators expression and subsequent DCV targeting into the axon.

Materials and methods {#sec012}
=====================

Ethical statement {#sec013}
-----------------

All animals were housed and bred according to institutional and Dutch Animal Ethical Committee regulations (DEC-FGA 11--03).

Laboratory animals and primary neuron cultures {#sec014}
----------------------------------------------

The generation of floxed *Camk2a* and *Camk2b* mice was previously described (Kool 2019). Postnatal day 1 (P1) pups were humanely killed, and hippocampi were dissected in Hank's balanced salt solution (HBSS Sigma) with 10 mM HEPES (Life Technology), digested in 0.025% trypsin (Life Technologies) for 20 minutes at 37°C and dissociated with fire-polished Pasteur pipettes. Dissociated neurons were resuspended in neurobasal supplemented with 2% B-27, 18 mM HEPES, 0.25% Glutamax, 0.1% penicillin/streptomycin (Life Technologies) and plated at a density of 1,300 neurons/well on astrocyte micro-island \[[@pbio.3000826.ref006], [@pbio.3000826.ref081], [@pbio.3000826.ref082]\] in 12-well plates; for high-density cultures 25,000 neurons/well were plated on pregrown glia cells. Astrocyte micro-island were generated by plating 6,000 rat glial cells per agarose-coated 18-mm glass coverslip, stamped with 0.1 mg/ml poly-D-lysine (Sigma) and 0.7 mg/ml rat tail collagen (BD Biosciences). For Western blots and qRT-PCR, neurons were plated at a density of 250,000 neurons/well on plates coated with a solution of 0.0005% Poly-L-ornithine, 2.5 μg/ml Laminin (Sigma). Neuronal cultures were kept in supplemented neurobasal at 37°C and 5% CO~2~.

Plasmid and lentiviral infection {#sec015}
--------------------------------

pCMV(pr)Camk2a-pCamkII(pr)eCFP and pCMV(pr)Camk2b-pCamkII(pr)eCFP were created by substituting tdTomato to eCFP from the plasmid in \[[@pbio.3000826.ref083]\]. pSyn(pr)Synapsin-mCherry \[[@pbio.3000826.ref039]\], pSyn(pr)BDNF-pHluorin, and pSyn(pr)BDNF-mCherry were engineered by replacing NPY with cDNA of BDNF from the plasmid encoding pSyn(pr)NPY-pHluorin \[[@pbio.3000826.ref038]\] and pSyn(pr)NPY-mCherry \[[@pbio.3000826.ref038]\]. pSyn(pr)NaV~II-III~-BFP was created substituting BFP from YFP in NaV~II-III~-YFP \[[@pbio.3000826.ref044], [@pbio.3000826.ref082]\]. A TetON expression system containing NPY-mCherry and mGFP was used for the trafficking experiments and to determine the axonal fusion of DCV \[[@pbio.3000826.ref006]\]. pCMV(pr)HA-NLS-Nrgn was produced as described in (Ma and colleagues 2014); pCMV(pr)HA-CaMKIV, pCMV(pr)HA-CREB-S133A, and pCMV(pr)HA-CREB-Y134F were cloned from a mouse cDNA library.

All plasmids were sequenced-verified and subcloned into lentiviral vectors to produce viral particles \[[@pbio.3000826.ref084]\].

Neuronal cultures were infected with Cre-recombinase 5 hours after plating to generate CaMK2-DKO or an inactive Cre \[[@pbio.3000826.ref036]\] as control. Rescue plasmids were added to the same mix. For experiments in [Fig 1](#pbio.3000826.g001){ref-type="fig"} and [Fig 2](#pbio.3000826.g002){ref-type="fig"}, viruses encoding the BDNF-pHluorin and Synapsin-mRFP were added to the neuronal culture 6 days before the readout. For experiments in [Fig 4A--4G](#pbio.3000826.g004){ref-type="fig"}, viruses encoding BDNF-mCherry and Nav~II-III~-YFP were added to the neuronal culture 3 days prior to live-cell imaging; experiments in [Fig 4H--4N](#pbio.3000826.g004){ref-type="fig"} are described next for sparse labeling. For experiments in [Fig 7A--7C](#pbio.3000826.g007){ref-type="fig"}, 0.2 μg/ml of BDNF antibody (DSHB) or 100 ng/ml or recombinant BDNF (Bio Connect) were added twice to the culture every 24 hours from DIV15, and cells were fixed 48 hours after the first administration. For experiments in [Fig 7D--7F](#pbio.3000826.g007){ref-type="fig"}, viruses encoding for TeNT-IRES2-mCherry were added 6 days before fixation. For experiments in [Fig 8](#pbio.3000826.g008){ref-type="fig"}, viruses encoding HA-CaMKIV, HA-NLS-Nrgn, and HA-CREB-Y134F were added to the culture 48 hours before fixation. Proper concentration of viruses was tested in WT cultures.

For sparse labeling with lentivirus particles, neurons were incubated in supplemented neurobasal with adequate amount of viral particles for 2 hours at 37°C, 5% CO~2~, washed in Dulbecco's modified Eagle medium (DMEM Life Technologies) containing 10% fetal calf serum (FCS), resuspended in supplemented neurobasal and plated 5,000 neurons/well on top of previously plated high-density culture, resulting in a 30,000 neuron/well cultures with 15% infected neurons/well. Expression was started 6 days before experiment by adding 2 g/ml doxycycline hyclate (Sigma).

Live-cell imaging {#sec016}
-----------------

Neurons at DIV 17--18 were placed in the imaging chamber containing Tyrode's solution (2 mM CaCl~2~, 2.5 mM KCl, 119 mM NaCl, 2 mM MgCl~2~, 30 mM glucose, 25 mM HEPES \[pH 7.4\]). Experiments were performed at room temperature (RT) with superfusion of Tyrode's buffer unless otherwise specified. Images were acquired on an Axiovert II microscope (Zeiss, Oberkochen, Germany) with a 40× oil objective (NA = 1.3) for SV fusion, DCV fusion, and trafficking, or on a Nikon Eclipse Ti microscope with 63× oil objective (NA = 1.4) for axonal targeting. Time-lapse recordings were acquired using Metamorph 6 (Molecular Devices <https://www.moleculardevices.com>) and an EM-CCD camera or using NisElements 4.30 software (NIKON, <https://www.microscope.healthcare.nikon.com>). The acquisition frequency was 2 Hz for pHluorin-based assays and 1 Hz for trafficking and targeting assays.

For SypHy experiments, the imaging protocol included 30 seconds of baseline recording, electrical field stimulation using a A-385 stimulus isolator (WPI) controlled by a Master 8 (AMPI), delivering 1-millisecond, 30-mA pulses for 5 seconds at 40 Hz, followed by 1 minute of recovery time and a final 5 seconds' perfusion with modified Tyrode's containing NH~4~Cl (2 mM CaCl~2~, 2.5 mM KCl, 119 mM NaCl, 2 mM MgCl~2~, 30 mM glucose, 25 mM HEPES, 50 mM NH~4~Cl \[pH 7.4\]) delivered by gravity flow through a capillary placed above the cell.

For DCV fusion, neurons were imaged for 30 seconds as baseline, stimulated with electrical field stimulation for 8 pulses of 1 second at 50 Hz separated by 0.5 seconds, allowed to rest for 30 seconds after which the stimulation was repeated. After an additional 30 seconds of recovery Tyrode's containing NH~4~Cl were superfused for 5 seconds.

For trafficking experiments, labeled neurons were identified, and the field of view was adjusted to fit the majority of the axon. After 30 seconds of baseline, electrical field stimulation was applied with 16 bursts of 1 second at 50 Hz separated by 0.5 seconds. For fluorescence recovery after photobleaching (FRAP) experiments, laser intensity and pulse duration for bleaching were optimized to reach \>90% fluorescence decrease of mCherry \[[@pbio.3000826.ref082]\], images were acquired for 180 seconds after an initial 5 seconds of baseline.

Immunostaining and confocal microscopy {#sec017}
--------------------------------------

Neurons were fixed at DIV18 with 3.7% formaldehyde (Merck) in phosphate-buffered saline (\[PBS\] 137mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 \[pH 7.4\]) for 20 minutes. Cells were permeabilized in 0.5% TritonX-100 (Fisher Chemical) for 5 minutes and blocked with 0.1% TritonX-100 and 2% normal goat serum for 60 minutes. Primary antibody incubation with MAP2 (Abcam, 1:1,000), SMI312 (Biolegend, 1:1,000), CaMK2 (SantaCruz, 1:350), VGLUT1 (Millipore, 1:5,000), BDNF (DSHB, 1:10) proBDNF(Alomene Labs, 1:300), CHGB (SySy, 1:500), SCG2 (Biodesign International, 1:1,000), synaptophysin 1 (SySy; 1:1,000), VAMP2 (SySy, 1:1,000), synaptotagmin 1 (W855 a kind gift from T. Südhof, Stanford, CA; 1:2000), MUNC18-1 (BD, 1:1,000), SNAP-25 (Abcam, 1:1,000), phosphoCREB-S133 (Abcam, 1:200) was performed for 2 hours at RT. Alexa Fluor conjugated secondary antibodies (1:1,000; Invitrogen) were incubated for 1 hour at RT. Coverslips were mounted in Mowiol and imaged on Nikon Eclipse Ti microscope confocal laser-scanning microscope (40× objective; NA 1.3) with NisElements 4.30 software. Images were acquired as Z-stack of 3 planes 250 μm apart and 4 images per plane with 15% overlap to ensure that the entire micro-island was in the field of view.

Western blot {#sec018}
------------

Hippocampal neurons were lysed at DIV18. Lysates were run on an SDS-PAGE and transferred to a polyvinylideenfluoride (PVDF) membrane (Bio-Rad). Membranes were blocked with 5% milk (Merk) in PBS with 0.1% Tween-20 (PBST) for 1 hour at RT; incubated in primary antibody against CaMK2 (Transduction lab, 1:2,500), CHGB (SySy, 1:1,000), SCG2 (GeneTex--bioconnect, 1:1,000), actin (Chemicon, 1:10,000) overnight at 4°C. Secondary alkaline phosphatase conjugated antibodies (Jackson Immuno Research, 1:10,000) were incubated for 30 minutes at RT. Membranes were visualized with AttoPhos (Promega) and scanned with a FLA-5,000 fluorescent image analyzer (Fujifilm).

Quantitative RT-PCR {#sec019}
-------------------

Total RNA was extracted from whole brains using UltraClean Tissue & Cells RNA Isolation kit (15000--50; MO BIO, Carlsbad, CA, USA). Synthesis of cDNA was performed using oligo d(T) and random hexamers with the kit iScriptTM select cDNA Synthesis Kit (1708896; BIO-RAD, Madrid, Spain). Quantitative RT-PCR was performed with SensiFastTM SYBR Lo-Rox kit (BIO-94005; BIOLINE, London, UK) using de Light Cycler 480 System (Roche Applied Science, Woerden, The Netherlands) with the following primers: SCG1-F:GTCCTCTCAAATGCCCTATCCA; SCG1-R:ACTTCGAGTTCTGGTTTTCACC; SCG2-F:GCTGTCCGGTGCTGAAA; SCG2-R:TTAGCTCCAGCCATGTCTTAAA; BDNF transcript2-F:CCATCCACACGTGACAAAAC; BDNF transcript2-R:GGTGCTGAATGGACTCTGCT; BDNF transcript4-F:GACCAGAAGCGTGACAACAA; BDNF transcript4-R:AGGGTCCACACAAAGCTCTC; eEF2a-F:CAATGGCAAAATCTCACTGC; and eEF2a-R:AACCTCATCTCTATTAAAAACACCAAA.

eEF2a was used as reference gene for normalizing the data across samples. The 2ΔΔCt method was used for calculating the fold change in expression of the different genes.

Image analysis {#sec020}
--------------

For SV fusion analysis, individual synapses were identified and treated as single region of interest (ROI) with a custom-made ImageJ algorithm (National Institute of Health); briefly, synapses were identify based on their increase in signal during NH~4~ application, if upon NH~4~ an ROI had a ΔF/F~0~ \< 4 \* StD(F~0~) + F~0~, where StD represents the standard deviation of the signal, the ROI was discarded. Individual traces were analyzed with a custom-made MATLAB (Mathworks, [www.mathworks.com](http://www.mathworks.com/)) script where synapses were quantified as active if the maximum ΔF/F~0~ upon stimulation was ≥ 3 \* StD(F~0~); active synapses were pooled per cell. SypHy fusion fraction was calculated as the ΔF~stimulation~ / ΔF~NH4~.

For DCV fusion, 2×2 pixel ROIs were placed semi-automatically, using a custom-made script in ImageJ, on all pHluorin region that appeared during the electrical stimulation. Individual traces were validated using a custom-made MATLAB script; only regions that showed an increase in ΔF/F~0~ \> 3 \* StD(F~0~) + F~0~ and with a rise time \<1 seconds were considered as positive fusion events. The total number of DCVs was calculated based on the NH~4~Cl response of individual recording with a custom-made ImageJ algorithm. Because of the overlap of DCVs in individual puncta, the number of vesicles was corrected normalizing the puncta intensity by the mode of the first percentile of the intensity distribution per cell.

For neuronal morphology and synaptic quantification, maximum intensity projections of confocal images were analyzed with a custom-made ImageJ algorithm, dendrites and axons based on Ridge detection, and their length was calculated based on the skeleton analysis in ImageJ; synapses were identified based on their intensity and dimension. For signal intensity, the intensity of each individual neuron was normalized to the average intensity of the WT condition in that biological replica.

For Western blot analysis, the band at the proper molecular weight was considered as an ROI. Intensity density was used to normalize the signal using the density of actin as reference. The adjusted signal was normalized to the signal of the WT condition.

For visualization purposes, brightness and contrast of representative examples were adjusted in a linear scale using the WT as reference. Saturation was always \<1% of the pixels and 0% of the pixels were set to undersaturation during adjustment.

Statistics {#sec021}
----------

Anderson--Darling test was used to test normality distribution of the data, and Levene's test for homogeneity of variances. When the assumptions for parametric tests were met, *t* test and 1-way ANOVA (post hoc Dunn--Sidak or Fisher) were used to test significant differences in the mean of the population. In case data were nonparametric, Mann--Whitney U and Kruskal--Wallis tests were used to test the significance of the median of the populations. All statistics were done in MATLAB, and their values are reported in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}.

Supporting information {#sec022}
======================

###### DCV fusion observed with BDNF-pHluorin.

BDNF, brain-derived neurotrophic factor; DCV, dense-core vesicle.

(MP4)

###### 

Click here for additional data file.

###### BDNF containing vesicles trafficking at the AIS.

AIS, axon initial segment; BDNF, brain-derived neurotrophic factor.

(MP4)

###### 

Click here for additional data file.

###### Axonal DCV trafficking observed with NPY-mCherry.

DCV, dense-core vesicle; NPY, neuropeptide Y.

(MP4)

###### 

Click here for additional data file.

###### CaMKII does not affect single vesicles' properties.

\(A\) Representative images of WT and DKO neurons infected with SypHy at the end of the electrical stimulation (left) and kymograph showing the dynamics of SypHy signal over time. (B) Average SypHy traces normalized as ΔF/F~0~. After 5 seconds of 40-Hz stimulation (light blue bar), neurons were allowed to rest for 60 seconds before NH~4~Cl superfusion to reveal the total amount of SypHy per synapses (light green bar). (C) Percentage of active synapses during a 40-Hz, 5-second stimulation. (D) SypHy fused fraction at the end of 5 seconds of 40-Hz stimulation. (E) Quantification of the decay constant τ for the SypHy signal intensity decay after stimulation. (F) Quantification of the SypHy signal upon NH~4~^+^ superfusion. (G) Typical neurite expressing BDNF-pHluorin during baseline, b, and during NH~4~^+^ superfusion, n. (H) Quantification of BDNF-pHluorin baseline fluorescence before stimulation. (I) Probability distribution of cells containing determined amount of BDNF-pHluorin positive puncta. (L) Average traces of BDNF-pHluorin fusion events aligned at the moment of fusion (0 seconds). (M) Histogram showing the BDNF-pHluorin signal intensity of individual fusion events. The fusion intensity was calculated as the fold change in fluorescence intensity from the 5 frames before fusion to the maximum intensity during fusion. (N) Quantification of average BDNF-pHluorin fusion intensity per cell. Traces show mean ± SEM (shaded area), boxplots with 95% CI whiskers, central bar is the median, white cross shows mean ± SEM. Columns and dots represent individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. Scale bar = 25 μm (A images), 50 μm (A kymograph); kymograph color map in 1A, NanoJ-Orange in ImageJ. BDNF, brain-derived neurotrophic factor; CaMK, Ca2+/calmodulin-dependent kinase II; CI, confidence interval; SypHy, synaptophysin-pHluorinl; WT, wild type.

(TIF)

###### 

Click here for additional data file.

###### CaMKII does not regulate expression of plasmids driven by Synapsin promoter.

\(A\) Typical images of neurites of WT (left) and DKO (right) immunostained for BDNF. Right, quantification of BDNF intensity at VGLUT1 labeled synapses in WT and DKO neurons. (B) Typical images of neurites of WT (left) and DKO (right) immunostained for CHGB. Right, quantification of CHGB intensity at VGLUT1 labeled synapses in WT and DKO neurons. (C) Typical images of neurites of WT (left) and DKO (right) expressing NPY-pHluorin. Right, quantification of NPY-pHluorin intensity at VGLUT1-labeled synapses in WT and DKO neurons. (D) Cumulative probability and average intensity for single BDNF puncta. (E) Cumulative probability and average intensity for single CHGB puncta. (F) Cumulative probability and average intensity for single NPY-pHluorin puncta. (G) Typical neurons overexpressing Synapsin-mCherry (H) Quantification of the average intensity of Synapsin-mCherry per cell. (I) Typical neuron overexpressing mGFP. (J) Quantification of average mGFP intensity in the total neuritic arbor. Boxplots with 95% CI whiskers, white cross shows mean ± SEM, central bar is the median. Columns and dots represent individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. Scale bar = 25 μm (G-I). BDNF, brain-derived neurotrophic factor; CaMKII, Ca2+/calmodulin-dependent kinase II; CHGB, chromogranin B; CI, confidence interval; DKO, double-knockout; mGFP, membrane-bound GFP; NPY, neuropeptide Y; SypHy, synaptophysin-pHluorin; VGLUT, vesicular glutamate transporter; WT, wild type.

(TIF)

###### 

Click here for additional data file.

###### Neuromodulators levels are not dependent on their distance from the soma.

\(A\) Typical images of neurites of WT (top) and DKO (bottom) immunostained for BDNF. Right, quantification of BDNF intensity at the soma of WT and DKO neurons. (B) Typical synapses immunostained for BDNF at the indicated distances from the soma. (C) Intensity profile of BDNF immunoreactivity in correlation to the distance from the soma. (D) Intensity profile of BDNF in VGLUT1 positive synapses in correlation to the distance from the soma. (E) Typical images of neurites of WT (top) and DKO (bottom) immunostained for CHGB. Right, quantification of CHGB intensity at the soma of WT and DKO neurons. (F) Typical synapses immunostained for CHGB at the indicated distances from the soma. (G) Intensity profile of CHGB immunoreactivity in correlation to the distance from the soma. (H) Intensity profile of CHGB in VGLUT1 positive synapses in correlation to the distance from the soma. (I) Typical images of neurites of WT (top) and DKO (bottom) expressing NPY-pHluorin. Right, quantification of NPY-pHluorin intensity at the soma of WT and DKO neurons. (J) Typical synapses expressing NPY-pHluorin at the indicated distances from the soma. (K) Intensity profile of NPY-pHluorin immunoreactivity in correlation to the distance from the soma. (L) Intensity profile of NPY-pHluorin in VGLUT1 positive synapses in correlation to the distance from the soma. Boxplots with 95% CI whiskers, white cross shows mean ± SEM, central bar is the median. Columns and dots represent individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. Full figure width = 36.46 μm (A-E-I) 4.25 μm (B-F-J). BDNF, brain-derived neurotrophic factor; CHGB, chromogranin B; CI, confidence interval; DKO, double-knockout; mGFP, membrane-bound GFP; NPY, neuropeptide Y; SypHy, synaptophysin-pHluorin; VGLUT, vesicular glutamate transporter; WT, wild type.

(TIF)

###### 

Click here for additional data file.

###### CaMKII negatively regulates neurites length and synaptogenesis.

\(A\) Typical neurons grown on astrocyte micro-island immunostained for the dendritic marker MAP2 (green) and the synaptic vesicle marker VGLUT1 (magenta). In the black and white bottom insert, the same neurons immunostained for CaMKII. (B) Quantification of average somatic CaMKII intensity. (C) Quantification of average dendritic length. (D) Quantification of synapse density (number of synapses per mm of dendrite). (E) Sholl analysis for the distribution of dendrite crossings. (F) Typical neurons grown on astrocytes micro-islands immunostained for the axonal marker SMI312 and synaptic vesicle marker VGLUT1. In zooms (bottom), light green lines define axons, and the VGLUT1 signal is inverted. (B) Quantification of average axonal length per cell in mm. (C) Quantification of synapse density (number of synapses per mm of axon). (D) Sholl analysis of synapse localization. (F) Sholl analysis for the distribution of axonal crossings. Traces shows mean ± SEM (shaded area), boxplots with 95% CI whiskers, white cross shows mean ± SEM. Columns and dots represent individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. Scale bar = 50 μm (A). CaMKII, Ca2+/calmodulin-dependent kinase II; MAP2, microtubule-associated protein 2; VGLUT, vesicular glutamate transporter; WT, wild type.

(TIF)

###### 

Click here for additional data file.

###### CaMKII does regulates the amount of BDNF vesicles entering the soma, not DCV trafficking.

\(A\) Schematic representation of AIS targeting; the region of the AIS was visualized by Na~v~II-III BFP. BDNF-mCherry vesicles were bleached at the AIS to allow quantification of new vesicles entering the axon. (B) Quantification of DCV flux at the AIS calculated as the number of BDNF-mCherry positive puncta that enter the Na~v~II-III BFP area per minute in retrograde (from the axon to the soma) direction. (C) Quantification of BDNF-mCherry speed at the AIS in the retrograde direction. (D) Quantification of the run length in μm at the AIS in the anterograde (left) and retrograde (right) direction. (E) Quantification of the pausing time, as percentace of the total moving time, at the AIS in the anterograde (left) and retrograde (right) direction. (F) Schematic representation of the TrkB endocytosis assay. Neurons were incubated with TrkB antibody for 30 minutes at 37°C. After fixation and prior to permeabilization, cultures were incubated with saturating concentration of secondary antibody. Endocytosed TrkB was visualized using standard immunostaining procedures. Bottom, typical WT neurites immunostained for MAP2 (green) and endocytosed TrkB (magenta). (G) Quantification of the average number of TrkB puncta per mm of MAP2 positive neurites. (H) Quantification of the average intensity of TrkB puncta. (I) Schematic representation of the surface TrfR assay. Neurons were incubated with Trf-Alexa-488 (Trf-488) antibody for 5 minutes after blocking endocytosis. Total amount of TrfR was visualized using standard immunostaining procedures. Bottom, typical WT neurites immunostained for Trf-488 (green) and TrfR (magenta). (J) Quantification of the total TrfR levels. (K) Quantification of the ratio between Trf-488 intensity to TrfR intensity. (L) Schematic representation of NPY-mCherry puncta moving in the anterograde and the retrograde direction in kymographs, light blue bars represent the stimulation of 16 trains of 50 APs at 50 Hz. Trafficking parameters were calculated before stimulation (B), during stimulation (S) and after stimulation (R). (M) Quantification of the axonal density of DCV moving in the anterograde and retrograde direction. (N) Quantification of the average speed (in μm/s) for NPY-mCherry puncta, per cell, in the anterograde and retrograde direction. (O) Quantification of the run length (in μm) for NPY-mCherry puncta, per cell, in the anterograde and retrograde direction. (P) Quantification of the percentage of time DCVs pause in the anterograde and retrograde direction. Traces shows mean ± SEM (shaded area), boxplots with 95% CI whiskers, white cross shows mean ± SEM, central bar is the median. Columns and dots represent individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. Scale bar = 25 μm (F-I). AIS, axon initial segment; BDNF, brain-derived neurotrophic factor; BFP, blue fluorescence protin; CaMKII, Ca2+/calmodulin-dependent kinase II; CHGB, chromogranin B; CI, confidence interval; DCV, dense-core vesicle; mGFP, membrane-bound GFP; Nav~II-III~, voltage-gated sodium channel intracellular domain; NPY, neuropeptide Y;; TrfR, transferrin receptor; TrkB, tyrosine receptor B; VGLUT, vesicular glutamate transporter; WT, wild type.

(TIF)

###### 

Click here for additional data file.

###### CREB phosphorylation at Ser-133 is required for BDNF accumulation in synapses.

\(A\) Typical example of the downstream pathway of βCaMKII that lead to pCREB at Ser-133. CREB phosphorylation can be enhanced in the absence of CaMKII by shuttling CaM via NLS-Nrgn, by activating CaMKIV or by lowering the threshold for PKA-mediated CREB-Y134F. (B) Percentage of cells that presented pCREB in unstimulated conditions. (C) Quantification of the relative intensity of BDNF in synapses of WT and DKO neurons left untreated or with expression of the phosphodead form of CREB (CREB-S133A). Boxplots with 95 CI whiskers, white cross shows mean ± SEM. Columns and dots represent individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. BDNF, brain-derived neurotrophic factor; CaM, calmodulin; CaMKII, Ca2+/calmodulin-dependent kinase II; CaMKIV, Ca2+/calmodulin-dependent kinase IV; CI, confidence interval; CREB, cAMP-response element binding protein; CREB-Y134F, phosphorylation of CREB with Tyr-to-Phe substitution at position 134; DKO, double-knockout; NLS-Nrgn, nuclear-localized neurogranin; pCREB, CREB phosphorylation; PKA, protein kinase A; WT, wild type.

(TIF)

###### 

Click here for additional data file.

###### α and βCaMKII have a different function in neuronal morphology.

\(A\) Typical neurons grown on astrocyte micro-islands immunostained for the dendritic marker MAP2 (green) and the SV marker VGLUT1 (magenta). (B) Average dendritic length in mm. (C) Synapse distribution expressed in the number of synapses per mm of dendrite. (D) Average axonal length in mm. Boxplots with 95 CI whiskers, white cross shows mean ± SEM. Columns and dots represent individual litters and neurons, respectively. The presented data can be found in [S1 Data](#pbio.3000826.s011){ref-type="supplementary-material"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. Scale bar = 50 μm (A). CaMKII, Ca2+/calmodulin-dependent kinase II; CI, confidence interval; MAP2, microtubule associated protein 2; SV, synaptic vesicle; VGLUT1, vesicular glutamate transporter 1.

(TIF)

###### 

Click here for additional data file.

###### Source data for each figure.

(XLSX)

###### 

Click here for additional data file.

###### Original immunoblot gel for [Fig 1](#pbio.3000826.g001){ref-type="fig"} and [Fig 5](#pbio.3000826.g005){ref-type="fig"}.

(PDF)

###### 

Click here for additional data file.
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AIS

:   axon initial segment

AMPA

:   alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

BDNF

:   brain-derived neurotrophic factor

BDNF2

:   BDNF transcript II

BDNF Ab

:   BDNF antibody

BFP

:   blue fluorescence protein

CaMK

:   Ca2+/calmodulin-dependent kinase

CHGB

:   chromogranin B

CREB

:   cAMP-response element binding protein

CREB-Y134F

:   phosphorylation of CREB with Tyr-to-Phe substitution at position 134

CREB-S133A

:   CREB with Ser-to-Ala substitution at position 133

DCV

:   dense-core vesicle

DIV

:   day in vitro

DKO

:   double-knockout

EPSC

:   excitatory postsynaptic current

F-actin

:   filamentous actin

GFP

:   green fluorescence protein

KD

:   kinase-dead

KIF

:   kinesin

LA

:   long-active

LTD

:   long-term depression

LTP

:   long-term potentiation

MAPK

:   mitogen-activated protein kinase

mGFP

:   membrane-bound GFP

mini-EPSC

:   miniature excitatory postsynaptic current

MUNC18

:   mammalian uncoordinated (UNC) 18

Nav~II-III~

:   voltage-gated sodium channel intracellular domain

NLS-Nrgn

:   nuclear-localized neurogranin

NMDA

:   N-methyl-D-aspartate

NMJ

:   neuromuscular junction

NPY

:   neuropeptide Y

pCREB

:   CREB phosphorylation

PSD

:   postsynaptic density

SNAP25

:   synaptosomal-associated protein 25

SNARE

:   soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor

SV

:   synaptic vesicle

SypHy

:   synaptophysin-pHluorin

Syn1

:   synapsin 1

Syt1

:   synaptotagmin 1

TeNT

:   tetanus neurotoxin

TetON

:   tetracycling inducible expression system

TrfR

:   transferrin receptor

TrkB

:   tyrosine receptor B

VAMP

:   vesicle-associated membrane protein

VGLUT1

:   vesicular glutamate transporter 1

WT

:   wild type
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6 Oct 2019

Dear Dr Verhage,

Thank you for submitting your manuscript entitled \"CaMKII controls neuromodulation via neuropeptide gene expression and axonal targeting of neuropeptide vesicles.\" for consideration as a Research Article by PLOS Biology.

Your manuscript has now been evaluated by the PLOS Biology editorial staff as well as by an academic editor with relevant expertise and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the \'Submissions Needing Revisions\' folder on your homepage. Please click \'Revise Submission\' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by Oct 08 2019 11:59PM.

Login to Editorial Manager here: <https://www.editorialmanager.com/pbiology>

During resubmission, you will be invited to opt-in to posting your pre-review manuscript as a bioRxiv preprint. Visit <http://journals.plos.org/plosbiology/s/preprints> for full details. If you consent to posting your current manuscript as a preprint, please upload a single Preprint PDF when you re-submit.

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email us at <plosbiology@plos.org> if you have any queries relating to your submission.

Kind regards,

Ines

\--

Ines Alvarez-Garcia, PhD

Senior Editor

PLOS Biology

Carlyle House, Carlyle Road

Cambridge, CB4 3DN

+44 1223--442810
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12 Nov 2019

Dear Dr Verhage,

Thank you very much for submitting your manuscript \"CaMKII controls neuromodulation via neuropeptide gene expression and axonal targeting of neuropeptide vesicles\" for consideration as a Research Article at PLOS Biology. Your manuscript has been evaluated by the PLOS Biology editors, an Academic Editor with relevant expertise, and by three independent reviewers.

The reviews of your manuscript are appended below. As you will see, the reviewers find the work potentially interesting, however they also feel that additional mechanistic insights would be required for this work to be appropriate for PLOS Biology. They would like you to focus on two aspects: 1) mechanisms on how CaMKII beta regulates BDNF transcription, and 2) how these findings relate to synapse development and plasticity.

Following a discussion with the Academic Editor, I regret that we cannot accept the current version of the manuscript for publication. We remain, however, interested in your study and we would be willing to consider resubmission of a comprehensively revised version that thoroughly addresses all the reviewers\' comments. We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers\' comments. Your revised manuscript would be sent for further evaluation by the reviewers.

We appreciate that these requests represent a great deal of extra work, and we are willing to relax our standard revision time to allow you \[six months\] to revise your manuscript. Please email us (<plosbiology@plos.org>) to discuss this if you have any questions or concerns, or think that you would need longer than this. At this stage, your manuscript remains formally under active consideration at our journal; please notify us by email if you do not wish to submit a revision and instead wish to pursue publication elsewhere, so that we may end consideration of the manuscript at PLOS Biology.

Your revisions should address the specific points made by each reviewer. Please submit a file detailing your responses to the editorial requests and a point-by-point response to all of the reviewers\' comments that indicates the changes you have made to the manuscript. In addition to a clean copy of the manuscript, please upload a \'track-changes\' version of your manuscript that specifies the edits made. This should be uploaded as a \"Related\" file type. You should also cite any additional relevant literature that has been published since the original submission and mention any additional citations in your response.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

Before you revise your manuscript, please review the following PLOS policy and formatting requirements checklist PDF: <http://journals.plos.org/plosbiology/s/file?id=9411/plos-biology-formatting-checklist.pdf>. It is helpful if you format your revision according to our requirements - should your paper subsequently be accepted, this will save time at the acceptance stage.

Please note that as a condition of publication PLOS\' data policy (<http://journals.plos.org/plosbiology/s/data-availability>) requires that you make available all data used to draw the conclusions arrived at in your manuscript. If you have not already done so, you must include any data used in your manuscript either in appropriate repositories, within the body of the manuscript, or as supporting information (N.B. this includes any numerical values that were used to generate graphs, histograms etc.). For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

For manuscripts submitted on or after 1st July 2019, we require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article\'s figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare them now, if you have not already uploaded them. Please carefully read our guidelines for how to prepare and upload this data: <https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements>.

Upon resubmission, the editors will assess your revision and if the editors and Academic Editor feel that the revised manuscript remains appropriate for the journal, we will send the manuscript for re-review. We aim to consult the same Academic Editor and reviewers for revised manuscripts but may consult others if needed.

If you still intend to submit a revised version of your manuscript, please go to <https://www.editorialmanager.com/pbiology/> and log in as an Author. Click the link labelled \'Submissions Needing Revision\' where you will find your submission record.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive thus far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Ines

\--

Ines Alvarez-Garcia, PhD

Senior Editor

PLOS Biology

Carlyle House, Carlyle Road

Cambridge, CB4 3DN

+44 1223--442810

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Reviewers\' comments

Rev. 1:

This manuscript provides clear evidence that CaMKII in general and especially CaMKII beta is important for proper expression of cargo of dense core vesicles (DCV) including BDNF and chromogranins.

Experiments are well executed and conclusions justified (but limited).

Major Concerns:

1\. My main concern is that the work is very focused and limited in scope. This manuscript would strongly profit if mechanistic insight into how CaMKII mediates its effect on cargo expression and secretory transport could be provided.

2\. Fig. 2A: vesicular SEP-BDNF content was only quantified with NH4 after high frequency stimulation. That should be systematically done without such stimulation under basal conditions.

3\. Fig. 2B: it seems the SEP-BDNF puncta density is comparable for lower densities but the higher densities seen in WT neurons are where DKO neurons fail to match-perhaps this distribution can be further analyzed and interpreted. Is there a limit/ceiling effect of maximal capacity for DCV density?

4\. The authors state: " the minor changes in Syb2, Munc18, and SNAP25 suggest that CaMKII has a minor role..." (top of p9). A 30% reduction in Munc18 and 23% reduction in SNAP25 is not minor and could perhaps should?) affect vesicle release.

Minor Concerns:

1\. BDNF is sometimes misspelled in Figures (Fig. 4B, left; Fig. 5B bottom BNDF2).

Rev. 2: Kang Shen - please note that this reviewer has waived anonymity

Moro et al., studied the effect of CaMKIIs on dense core vesicle trafficking, release and neuropeptide expression in hippocampal neurons. They found that CaMKIIs increases the expression of multiple neuropeptide genes, most likely through regulation of transcription, an effect that is mostly carried out by the betaCaMKII. They also reported that the CaMKIIs increased the transport of DCVs into the axon but does not play a major effect on the release of DCVs. The strength of this manuscript lies in two folds. First they have taken the stringent genetic approach and examined the alpha and beta CaMKII double knockout cells. This clearly eliminated any specificity concerns from the pharmacology experiments and the rescue experiments demonstrated convincingly that the effects of these knockouts are due to CaMKIIs. Secondly, they have examined DCV release with single vesicle resolution which was not done in C. elegans. The weakness of the manuscript lies in the fact that the conceptual advance is rather limited. The regulation of CaMKII on BDNF transcription has been shown using drug experiments in mouse. The effect of CaMKII mutation in DCV abundance has been characterized in C. elegans. This manuscript confirmed these observations in mouse with a stringent experimental approach and showed that beta CaMKII is playing a more important role. However, the mechanisms of these effects are not explored. For example, examining the phosphorylation of CREB would be a potential way to know if the transcriptional effect is due to CREB. In the mammalian literature, CaMKIV has been more linked to CREB phosphorylation.

Below are my other technical comments.

In Fig. 1, is the fluorescence intensity before stimulation the same between wt and DKO?

In Fig. 4, only the frequency of DCV movements was quantified. The authors should also quantify the speed and pauses of these movements. These information will further provide some insight in what is causing the reduced DCV entry into axon.

Line 143 "our data demonstrate that CaMKII regulates neuromodulation by lowering the

number of available DCVs and that is not involved in the fusion of SVs or the mechanism of fusion of DCVs in hippocampal neurons." Shouldn't this be increasing the number of DCV?

Line 258 "Therefore, CaMKII does not regulate the trafficking of DCVs in the axon but not take part in the

259 stimulation dependent arrest of trafficking vesicles." This sentence is problematic. Shouldn't it be "CaMKII does regulate..."?

Rev. 3:

In this study, the authors investigated the necessity of alpha- and beta-CaMKII in the secretion of BDNF, a well-established neuromodulator in synapse development and plasticity using mouse alpha- and beta-CaMKII deficient, hippocampal cultured neurons. The findings were novel and interesting. However, the manuscript in the current form requires substantial data to solidify sufficiency or necessity of either alpha- or beta-CaMKII in general neuromodulator secretion, given that most of findings were derived from exogenous overexpression of BDNF pHluorin only. In addition, the authors may want to show significance of their findings in conjunction with synapse development and/or plasticity. Therefore, the authors should perform experiments to test whether the loss of alpha- and beta- CaMKII affects- 1) synaptic vesicle secretion using vGlut- or synaptobrevin-pHluorin (or electrophysiological recordings), 2) exocytosis of general cargos using transferrin-receptor-pHluorin from dendrites. These experiments will confirm the authors' claim on the regulatory role of alpha- and beta- CaMKII on neuromodulators.

Minor points:

1\. Is the number of BDNF puncta reduced in the distal dendrite of DKO neurons? Did the authors perform any detailed quantification of BDNF puncta in relation to their distances from the soma?

2\. The authors may want to include recovery kinetics from FRAP experiments in Figure 4C and D.

3\. BDNF was misspelled in multiple places (Figures 1G, 4B, and 5B).

4\. Based on supplementary Fig 8, the overexpression of beta-CaMKII resulted in dramatic morphological changes. Why?

10.1371/journal.pbio.3000826.r003
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Click here for additional data file.
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23 Jun 2020

Dear Dr Verhage,

Thank you for submitting your revised Research Article entitled \"CaMKII controls neuromodulation via neuropeptide gene expression and axonal targeting of neuropeptide vesicles\" for publication in PLOS Biology. I have now obtained advice from the three original reviewers and have discussed their comments with the Academic Editor.

We\'re delighted to let you know that we\'re now editorially satisfied with your manuscript. However before we can formally accept your paper and consider it \"in press\", we also need to ensure that your article conforms to our guidelines. A member of our team will be in touch shortly with a set of requests. As we can\'t proceed until these requirements are met, your swift response will help prevent delays to publication. Please also make sure to address the data and other policy-related requests noted at the end of this email.

\*Copyediting\*

Upon acceptance of your article, your final files will be copyedited and typeset into the final PDF. While you will have an opportunity to review these files as proofs, PLOS will only permit corrections to spelling or significant scientific errors. Therefore, please take this final revision time to assess and make any remaining major changes to your manuscript.

NOTE: If Supporting Information files are included with your article, note that these are not copyedited and will be published as they are submitted. Please ensure that these files are legible and of high quality (at least 300 dpi) in an easily accessible file format. For this reason, please be aware that any references listed in an SI file will not be indexed. For more information, see our Supporting Information guidelines:

<https://journals.plos.org/plosbiology/s/supporting-information>

\*Published Peer Review History\*

Please note that you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

<https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/>

\*Early Version\*

Please note that an uncorrected proof of your manuscript will be published online ahead of the final version, unless you opted out when submitting your manuscript. If, for any reason, you do not want an earlier version of your manuscript published online, uncheck the box. Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us as soon as possible if you or your institution is planning to press release the article.

\*Protocols deposition\*

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <https://journals.plos.org/plosbiology/s/submission-guidelines#loc-materials-and-methods>

\*Submitting Your Revision\*

To submit your revision, please go to <https://www.editorialmanager.com/pbiology/> and log in as an Author. Click the link labelled \'Submissions Needing Revision\' to find your submission record. Your revised submission must include a cover letter, a Response to Reviewers file that provides a detailed response to the reviewers\' comments (if applicable), and a track-changes file indicating any changes that you have made to the manuscript.

Please do not hesitate to contact me should you have any questions.

Sincerely,

Ines

\--

Ines Alvarez-Garcia, PhD

Senior Editor

PLOS Biology

<ialvarez-garcia@plos.org>

Carlyle House, Carlyle Road

Cambridge, CB4 3DN

+44 1223--442810

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

DATA POLICY:

Thank you for sending us the file containing all the data underlying the graphs shown in the figures. I have checked the data and found a few mistakes and missing data that should be addressed:

Fig. 3L -- please correct label (at the moment it's 3K)

Fig. 5B -- please correct the label of BDNF4 data (at the moment it's BDNF2)

Fig. S7 - please relabel (at the moment it's S4) and add the data of Fig. S7C, C, G, H, D, E, J, K, M, N

Fig. S9A -- please add the data

In addition, please indicate in each figure legend (including those from the Supplementary figures) WHERE THE UNDERLYING DATA CAN BE FOUND.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Reviewers' comments

Rev. 1:

The Authors addressed the concerns well, including providing further mechanistic insight.

Rev. 2:

The new data added to this manuscript has significantly extended the scope for this paper. The authors have also addressed my questions. I have no more questions.

Rev. 3:

The authors addressed all of my concerns by performing additional experiments. I have no further comment.

10.1371/journal.pbio.3000826.r005
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17 Jul 2020

Dear Dr Verhage,

On behalf of my colleagues and the Academic Editor, Eunjoon Kim, I am pleased to inform you that we will be delighted to publish your Research Article in PLOS Biology.

The files will now enter our production system. You will receive a copyedited version of the manuscript, along with your figures for a final review. You will be given two business days to review and approve the copyedit. Then, within a week, you will receive a PDF proof of your typeset article. You will have two days to review the PDF and make any final corrections. If there is a chance that you\'ll be unavailable during the copy editing/proof review period, please provide us with contact details of one of the other authors whom you nominate to handle these stages on your behalf. This will ensure that any requested corrections reach the production department in time for publication.

Early Version

The version of your manuscript submitted at the copyedit stage will be posted online ahead of the final proof version, unless you have already opted out of the process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with <biologypress@plos.org>. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit <http://www.plos.org/about/media-inquiries/embargo-policy/>.

Thank you again for submitting your manuscript to PLOS Biology and for your support of Open Access publishing. Please do not hesitate to contact me if I can provide any assistance during the production process.

Kind regards,

Vita Usova

Publication Assistant,

PLOS Biology

on behalf of

Ines Alvarez-Garcia,

Senior Editor

PLOS Biology

[^1]: The authors have declared that no competing interests exist.
